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ABSTRACT 
 
In recent years, the development of follow-on biological products (biosimilars) 
has received increasing attention. The dissertation covers statistical methods 
related to three topics of Non-inferiority (NI), Bioequivalence (BE) and 
Equivalence in demonstrating biosimilarity. For NI, one of the key requirements is 
constancy assumption, that is, the effect of reference treatment is the same in 
current NI trials as in historical superiority trials. However if a covariate interacts 
with the treatment arms, then changes in distribution of this covariate will result in 
violation of constancy assumption. We propose a modified covariate-adjustment 
fixed margin method, and recommend it based on its performance characteristics 
in comparison with other methods. Topic two is related to BE inference for log-
normal distributed data. Two drugs are bioequivalent if the difference of a 
pharmacokinetics (PK) parameter of two products falls within prespecified 
margins. In the presence of unspecified variances, existing methods like two one-
sided tests and Bayesian analysis in BE setting limit our knowledge on the extent 
that inference of BE is affected by the variability of the PK parameter. We 
vi 
propose a likelihood approach that retains the unspecified variances in the model 
and partitions the entire likelihood function into two components: F-statistic 
function for variances and t-statistic function for difference of PK parameter. The 
advantage of the proposed method over existing methods is it helps identify 
range of variances where BE is more likely to be achieved. In the third topic, we 
extend the proposed likelihood method for Equivalence inference, where data is 
often normal distributed. In this part, we demonstrate an additional advantage of 
the proposed method over current analysis methods such as likelihood ratio test 
and Bayesian analysis in Equivalence setting. The proposed likelihood method 
produces results that are same or comparable to current analysis methods in 
general case when model parameters are independent. However it yields better 
results in special cases when model parameters are dependent, for example the 
ratio of variances is directly proportional to the ratio of means. Our research 
results suggest the proposed likelihood method serves a better alternative than 
the current analysis methods to address BE/Equivalence inference.  
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1.  Introduction 
 
 
 
A small molecule drug is defined as a drug manufactured through a chemical 
process and can be structurally replicated. As such, the process to approve a 
generic version of a small molecule is well defined. On the other hand, biologics 
are often hundreds of times the size of a small molecule and a quite complex. 
These products, often proteins, are produced via living cells. The manufacturing 
of these products is never completely pure and there is natural variation between 
production lots. Therefore, regulatory authorization on biosimilars cannot follow 
the precedent set by small molecule generics.  
According the FDA guidance document (2012) they define biosimilar “the 
biological product is highly similar to the reference product notwithstanding minor 
differences in clinically inactive components”, and that “there are no clinically 
meaningful differences between the biological product and the reference product 
in terms of the safety, purity, and potency of the product”. FDA recommends 
“stepwise approach” to develop biosimilar products. A stepwise approach 
includes “a comparison of the proposed product and the reference product with 
respect to structure, function, animal toxicity, human pharmacokinetics (PK) and 
pharmacodynamics (PD), clinical immunogenicity, and clinical safety and 
effectiveness.” Biopharmaceutical companies are heading towards 
  
 
2
demonstrating a proposed therapeutic protein product is biosimilar to a licensed 
reference product after the Patient Protection and Affordable Care Act signed 
into law by President Barack Obama in 2010.  
In biosimilar problems, the three most important terminologies are 
Bioequivalence (BE), Non-Inferiority (NI) and Equivalence. For small molecules, 
establishment of BE is a regulatory requirement prior to claiming that the 
proposed generic version is equivalent to the branded-name drug. For example, 
according to regulations applicable in the European Economic Area, two 
medicinal products are bioequivalent if they are pharmaceutically equivalent and 
if their bioavailabilities after administration in the same molar doses are similar to 
such a degree that their effects, with respect to both efficacy and safety, will be 
essentially the same. A similar wording of the BE definition can found in the US 
FDA guidelines (FDA guidance 2001). Thus the definitions of BE place the focus 
of statistical inference on whether the parameter of interest falls within the 
equivalence margins more rigorously than estimating the parameter itself. It is 
very likely to have similar regulatory understanding of BE for biologics, although 
has not been well established yet. For NI and equivalence trials we are looking at 
the endpoint of interest (often efficacy), so we are looking at the actual measure 
of interest (unlike BE where we are looking at a ‘biomarker’). NI is to show we are 
not worse than the reference product. Equivalence is not only looking at the 
lower bound (non-inferior) but also an upper bound (non-superior). The NI 
margins and equivalence margins can be derived in the same way.  
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My dissertation research arose from clinical trials in demonstrating biosimilarity. 
The thesis will cover three broad inter related ideas on testing for BE (used in 
Phase I, II for PK variables), NI and Equivalence (used in Phase III for efficacy 
endpoint).  
1. Current NI methods re-evaluated 
2. A likelihood method of evaluating BE 
3. Extension of BE evaluation method to Equivalence  
One of the key assumptions on the NI test is constancy assumption, that is, the 
effect of reference treatment is the same in current NI trials as in historical 
superiority trials. However, if a covariate interacts with the treatment arms, then 
changes in distribution of this covariate will likely result in violation of constancy 
assumption. In the first part of the dissertation, we propose four new NI methods 
and compare them with two existing methods to evaluate the change of 
background constancy assumption on the performance of these six methods. To 
achieve this goal, we study the impact of three elements: 1) Strength of 
covariate; 2) Degree of interaction between covariate and treatment and; 3) 
Differences in distribution of the covariate between historical and current trials 
have on both the type I error rate and power using three different measures of 
association: difference, log relative risk and log odds ratio.  
Two drugs are bioequivalent if the ratio of a pharmacokinetic (PK) parameter of 
two products falls within equivalence margins. The distribution of PK parameters 
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is often assumed to be log-normal, therefore bioequivalence (BE) is usually 
assessed on the difference of logarithmically transformed PK parameters (). In 
the presence of unspecified variances, test procedures like two one-sided tests 
(TOST) use sample estimates for those variances; profile likelihood replaces 
them with restricted maximum likelihood estimators, while Bayesian models 
integrate them out in the posterior distribution. These methods limit our 
knowledge on the extent that inference about BE is affected by the variability of 
PK parameters. In the second part of the dissertation, we propose a likelihood 
approach that retains the unspecified variances in the model and partitions the 
entire likelihood function into two components: F-statistic function for variances 
and t-statistic function for . Demonstrated with published real life data, the 
proposed method not only produces results that are same as TOST and 
comparable to Bayesian method, but also helps identify ranges of variances 
which could make the determination of BE more achievable. Our findings 
manifest the advantages of the proposed method in making inference about the 
extent that BE is affected by the unspecified variances, which cannot be 
accomplished either by TOST or Bayesian method.  
Equivalence trials aim to demonstrate that new and standard treatments are 
equivalent within pre-defined clinically relevant limits. We focus when inference 
of equivalence is made in terms of the ratio of two normal means. In the 
presence of unspecified variances, methods such as likelihood-ratio test use 
sample estimates for those variances; Bayesian models integrate them out in the 
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posterior distribution. These methods limit our knowledge on the extent that 
inference about equivalence is affected by variability of the parameter of interest. 
To account the presence of unspecified variances, in the third part, we extend 
the likelihood approach from log-normal data to normal data. The proposed 
method retains the unspecified variances in the model and partitions the full-
likelihood function into two components: F-statistic function for variances and t-
statistic function for the ratio of means. We show that, the proposed method can 
help identify ranges of variances where equivalence is more likely to be 
achieved. In addition, the proposed method can produce results that are same as 
the likelihood-ratio test and comparable to Bayesian analysis in general case 
when model parameters are independent. In a special case of dependent 
parameters, for example the ratio of two variances is directly proportional to the 
ratio of two means, the proposed method yields better results in inference about 
equivalence than the likelihood-ratio test which relies solely on the t-statistic or 
Bayesian analysis which integrates out the variances over some non-informative 
prior in the posterior distribution.   
The aim of this dissertation is to develop advanced methodology/procedures in 
BE, NI and equivalence testing. We have written these three topics to 
methodology manuscripts and submitted to peer-review statistical journals, so 
each topic in the dissertation is self contained. The proposed work is the first in 
this specific area, and will help in developing effective ways to demonstrate 
whether new products are biosimilar to reference products.  
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2.  Covariate effect on constancy assumption in noninferiority clinical trials 
(First Topic) 
 
 
 
2.1. Introduction 
 
 
Superiority test is the standard statistical test employed in the randomized clinical 
trial (RCT) [16, 36] with the aim to show that one treatment is superior to the 
other. However, given changes in patient populations, quality of life, and 
treatment options, it is becoming increasingly difficult to develop a clinically more 
efficacious new treatment. It is also often unethical to give patients placebo when 
an active treatment is available on the market. Therefore, pharmaceutical 
companies are now more interested in developing new treatments by showing 
that they are equivalent or non-inferior to an existing treatment. In these cases 
the focus has shifted from statistical significance to clinical meaningful difference 
and comparability. The Patient and Affordable Care Act of 2010 has also led to 
further influx of non-inferiority and equivalence clinical trials designs.  
To avoid misuse of superiority test, non-inferior tests are more appropriate, in 
which significant results lead to conclusion of non-inferiority that is not due to 
sampling error [34, 50]. An overall improvement in patient care is taken into 
consideration in addition to establishment of non-inferiority for efficacy endpoint. 
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For example, if the new treatment also shows other benefits, such as cheaper 
price for the new drug, easier mode of administration (subcutaneous or oral 
instead of an intravenous administration), less toxicity and so on. 
Unlike superiority test which directly demonstrates the efficacy of a test 
treatment, non-inferiority test is an indirect approach to demonstrate the efficacy 
of a test treatment. NI test combines current NI trial, which compares test 
treatment with reference treatment, with one or more historical superiority trials, 
which compared reference treatment with placebo [25, 28]. In order to do this, 
one of the key assumptions of the NI test is the constancy assumption, i.e., the 
effect of reference treatment is the same in current NI trial as in historical 
superiority trials [12, 13, 18, 23]. However, this assumption may not hold due to 
differences in the inclusion/exclusion criteria between current trial and historical 
trials, mode of administration, length of follow-up, design quality etc. When the 
constancy assumption is violated, standard statistical methods—fixed margin 
method and synthesis method may become invalid, as shown by Wang et al. 
[49].   
If a covariate is associated with the effect size of the reference product, changes 
in distribution of this covariate will result in violation of the constancy assumption. 
Nie and Soon [35] proposed a covariate-adjustment regression model approach 
to assess the test treatment effect when population difference between the 
historical trial and the current NI trial causes constancy assumption violation. 
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However, they did not compare performance characteristics of proposed 
methods with standard methods. Moreover, adjustment of treatment effect was 
made only when the constancy assumption was violated. They did not take 
advantage of the fact that the reference treatment effect was estimable using the 
covariate mean of the new population based on the model-based regression 
approach. Reference treatment effect estimated using the current population is 
more accurate than using historical trial population for NI test, regardless of 
violation of the constancy assumption. Furthermore, the covariate effect was 
evaluated and estimated using historical data, but was not confirmed using the NI 
data.  
In this topic, we propose modified covariate-adjustment fixed margin/synthesis 
methods and two-stage covariate-adjustment fixed margin/synthesis methods. 
For the modified covariate-adjustment fixed margin/synthesis methods, we 
estimate the effect size of reference product using covariate mean of current 
population. For the two-stage covariate-adjustment fixed margin/synthesis 
methods, the first stage is to assess whether the effect of covariate is important 
enough to be included in the model using current NI data, and the second stage 
is to use either the fixed margin/synthesis methods (if covariate not included) or 
modified covariate-adjustment fixed margin/synthesis methods (if covariate 
included) based on the results of the first stage. We will also study the impact of 
three elements: 1) Strength of covariate; 2) Degree of interaction between 
covariate and treatment; and 3) Differences in distribution of the covariate 
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between historical and current trials have on both the type I error rate and power 
using three different measures of association: difference, log relative risk and log 
odds ratio.    
Note that the covariate-adjustment fixed margin/synthesis approach requires 
individual patient data (IPD) rather than aggregate data (AD) in historical trial Nie 
and Soon [35]. IPD are complete data information including each patient’s 
assigned treatment arm, outcome and covariate measurements. IPD is the gold 
standard for meta-analysis to obtain historical estimates [8, 44]. If the 
investigators of both NI and the historical trials are the same, there should be no 
problem to access the raw data. However, if the investigators are different, then 
sharing data among sponsors/regulatory agencies are encouraged to design 
future NI trials.  
For simplicity, we assume 1:1 balanced randomized clinical trials, with patient-
level data available, and focus on factors whose impact on treatment difference 
can be quantified, for example population differences. We will address the 
question of how the changes of background distribution (i.e. violation of 
constancy assumption) will affect the performance of various NI methods, using 
the three different measures of association (difference, log relative risk and log 
odds ratio). Section 2.2 will describe the methods. Section 2.3 will give the details 
of the simulation set up and the results of various simulations. Section 2.4 will 
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summarize our conclusions on the performance evaluation based on type I error 
rate, power and some relevant sensitively analysis.  
 
 
 
2.2. NI Test Problem and Methods 
 
 
Suppose the outcome is a dichotomous efficacy variable. For convenience we 
will assume that a higher response rate is desirable (if the opposite is true one 
can always just multiple by negative one to get the desired direction). Let T, C, 
and P be response rates of test drug, active control drug and putative placebo in 
NI trial, respectively. Let  and  be response rates of active control drug and 
placebo in historical trial, respectively. Note that active control is the reference 
product. In NI trials there is no placebo arm, but sponsors and regulatory 
agencies are still usually interested in estimating what the effect size of test 
product over placebo would have been if the placebo had been included in the 
current NI trial. Since no direct comparison is available, we impute a placebo, 
called a putative placebo, from historical data to assist in this indirect 
comparison.  
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Figure 2.1.  Plot for response rates of test drug (T), active control drug (C) and 
putative placebo (P) in NI trial. 
 
Figure 2.1 shows the relationship among response rates of test drug (T), active 
control drug (C) and putative placebo (P) in NI trial. “0” is included to indicate 
direction.  
Formulation of the hypothesis depends on the primary objectives. According to 
Blackwelder [6], the general objective of NI is to show the test treatment is not 
worse than the active control by a pre-specified margin, that is  
: C  T    vs.  : C  T                                               (1) 
C-T stands for “difference” between active control and test product, it could be 
difference, relative risk, odds ratio, log of relative risk or log of odds ratio 
(mathematic expression can be modified accordingly). The margin  is the 
largest acceptable difference between the two products that would be considered 
not clinically meaningful and must be carefully defined in advance. Selection of 
the margin  is extremely challenging, involving both careful clinical and 
statistical judgments [12, 13, 18, 23, 24, 27, 48].  
The minimum standard for regulatory agencies’ approval of a test treatment is to 
show “superiority over placebo”. However, with missing placebo arm in active 
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controlled clinical trials, direct demonstration of such superiority is impossible. 
Furthermore, with reference products have already been marketed for years with 
positive risk-benefit profiles, “superiority over placebo” is a necessary but not 
sufficient condition to approve a test product. The goal is to choose a margin so 
that the test product retains some fraction of reference product efficacy (FDA, 
1999). If all uncertainties are properly and comprehensively considered, ruling 
out the margin  within an acceptable statistical error from the non inferiority trial 
can be helpful in also demonstrating superiority over placebo with great 
confidence.  
Given an objective of retaining a portion of the active control treatment efficacy, 
equation (1) can be rewritten as equation (2): 
       : C  T  1  C  P vs.    : C  T  1                      (2) 
where λ  is the level of percent effect retention from previous active trial. A key 
question is what estimate to use for C-P? Does one use the point estimate or 
should one use a more conservative estimate? Regulatory guidance document 
suggests using a lower bound of a confidence interval and/or taking “discount” of 
any related uncertainties. Note that such estimate of effect size of reference 
product can be either point estimate or lower bound of some confidence interval, 
or taking “discount” of any related uncertainties [45]. Our discussions below are 
based on the retention test hypothesis (2).  
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2.2.1. Fixed margin method 
 
 
This method rejects the null hypothesis  in (2) and concludes that the test 
treatment is not inferior to the reference treatment if 
                        ! " #α$%&  1  '(  )  #α$*&+                               (3) 
where zα is the (1- α)th percentile of the standard normal distribution. ( and ) 
are estimators of C and P from historical trial, $*& estimates the standard error 
of (C-P). Similarly,  and  -  are estimators of C and T from current NI trial, $%& 
estimates the standard error of (C-T).  
The non-inferiority margin  is a function (often taking the smaller value) of a 
statistical margin and a clinical margin, and must be predetermined before the NI 
trial starts. However, when conducting this NI analysis, the margin is treated as a 
fixed constant. The clinical margin comes from a comprehensive review of 
literature combined with clinical judgment. While a statistical margin often comes 
from an analysis of one or more historical superiority trials. In this paper we will 
assume that the statistical margin is smaller than the clinical margin, but we 
should bear in mind that choosing a fixed margin is always combining both the 
statistical and the clinical information.  
If we use α 
 0.025, the fixed margin method is known as 95-95 method, where 
the first 95 means the 95% confidence interval obtained from the historical trial, 
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and the second 95 means the 95% confidence interval obtained from the non 
inferiority trial. The fixed margin method is also known as confidence interval 
method. This method is conservative due to the fact that the margin is 
determined by discounting the lower bound of (  ). For further details of this 
method, please refer Hung et al., [23]; Hung et al., [24]; Hung et al., [25]; Wang 
et al., [47]; Wang and Hung, [48];Tsong et al., [46]; Wiens, [52]; Laster et al., [30] 
and references therein.  
 
2.2.2. Synthesis method 
 
 
Synthesis method rejects the null hypothesis  in (2) if 
                 234 
 &5 %! 556'&(75*)7+89:;< =56<9>;7<  #α                                            (4) 
where zα is the (1-?)th percentile of the standard normal distribution. This method 
is also known as preservation test method.  
This method synthesizes two sources of data—current NI study (estimates the 
effect of test treatment over reference treatment     ! ) and historical studies 
(estimated the effect of reference treatment over placebo (  )). Here there is 
no need to pre-specify a non-inferiority margin. (  ) is not a fixed constant but 
an additional random variable similar to the random variable     ! . Because the 
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test statistic is constructed by dividing a relevant combination of the estimate of 
test treatment effect and active control effect by the combined standard error, this 
method purports to control type I error rate under the constancy assumption. 
Since the variance of fixed margin method is larger than the variance of 
synthesis method, the fixed margin method is more conservative and hence the 
nominal type I error rate is often much less than the desired target type I error 
rate (even when the constancy assumption holds). The synthesis method has 
been shown to be very sensitive to the constancy assumption. Violation of the 
constancy assumption will result in the synthesis method being liberal. However, 
since the fixed margin method uses the worst limit of the confidence interval of 
the active control effect to define the margin, it may be less sensitive to the 
violations of the constancy condition. The degree of which depends on the level 
of preservation specified in the defining the margin.  For more details of this 
method, please refer Hung et al., [23]; Wang et al., [49]; Wang and Hung, [48]; 
Snapinn, [45]; Hasselblad and Kong, [19]; ICH, [26]; Holmgren, [21]; Wang and 
Hung, [47]; Rothmann et al., [37] and references therein.  
 
2.2.3. Modified covariate-adjustment fixed margin/synthesis methods 
 
 
Nie and Soon [35] proposed a covariate-adjustment regression model approach 
to assess the test treatment effect when population difference between the 
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historical trial and the NI trial causes constancy assumption violation. Applying 
this approach, they were not only able to measure the impact of population 
difference on the degree of constancy assumption violation, but were also able to 
re-estimate the effect size of the active control when constancy assumption did 
not hold. For historical superiority trial, the following logistic model is used to 
describe association between dichotomous outcome, treatment arm and 
covariate: 
          @ABCDEF 
 1G 
 ? " H I  JD " H I K " L I K I  JD                        (5) 
, where Y is the primary efficacy endpoint (outcome); Trt is the treatment arm, 1 
for placebo and 0 for reference product; X is a binary covariate, coded as 1 or 0, 
and K I  JD is the interaction term for treatment and covariate. This basic model 
can easily extend to a more complicated one, such as including two or more 
covariates, and some of them may be independent from treatment arm. 
Individual patient data is needed for this modeling.  
Based on the above model, the effect of active control is @ABCD  @ABCD 
H  LKM·O, where KM·O is the mean of covariate X for historical trial population. NI 
trial population can also be used to estimate the mean of covariate X. Constancy 
assumption holds if the difference between such effects using two populations is 
small. To estimate the effect size of active control, current NI trial population is 
preferable if it is available; otherwise, the historical population can be used to 
estimate this. We modified Nie and Soon’s method by always using covariate 
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mean of current NI trial population, because it will give us a more accurate 
estimator of active control efficacy in NI test. We further apply this active control 
effect to 2.1 and 2.2 for modified covariate-adjustment fixed margin method and 
modified covariate-adjustment synthesis method.  
a) Modified covariate-adjustment fixed margin method (CovFM) 
Replace the estimator of (  ) and its standard error $*& in (3) using 
parameters estimated in (5) and covariate mean of current NI trial population. 
b) Modified covariate-adjustment synthesis method (CovSyn) 
Replace the estimator of (  ) and its standard error $*& in (4) using 
parameters estimated in (5) and covariate mean of current NI trial population. 
 
2.2.4. Two-stage covariate-adjustment fixed margin/synthesis methods 
 
 
Often one does not know the true effect of a covariate. In section 2.3 modified 
covariate-adjustment method, the covariate effect was confirmed via model 
selection using historical data, and did not use current NI data. In the proposed 
two-stage method, the first stage is to confirm that the effect of covariate is 
sufficiently present in the current study to such an extent that it should be 
incorporated in the current analysis; the second stage is to use either the 
covariate method or unadjusted method based on the results of stage 1.  
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Stage 1: Test of covariate 
For a given NI trial, suppose PP and PPQ are response rates of subgroups 
defined by a binomial covariate. To confirm the effect of covariate in the first 
stage, we propose the following hypothesis test using threshold 0.15 instead of 
commonly used 0.05:  
             : PP 
 PPQ vs. R: PP S PPQ                                     (6) 
 
Stage 2: Test of NI 
In stage 2, use fixed margin method or synthesis method if the null hypothesis in 
stage 1 is not rejected, i.e., the effect of covariate is not worth putting into the 
model; use modified covariate-adjustment fixed margin method or modified 
covariate-adjustment synthesis method if null hypothesis can be rejected. We will 
denote the above by two-stage covariate-adjustment fixed margin method if the 
fixed margin method is used in stage 2 and two-stage covariate-adjustment 
synthesis method if the synthesis method is used in stage 2.  
 
2.2.5. Paradigms of the two NI Methods: Fixed margin vs. Synthesis 
 
 
All methods used here involve using either the fixed margin approach or the 
synthesis approach. Note that these two approaches operate under different sets 
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of paradigms. The fixed margin method uses conventional clinical trial inference, 
which is based on a comparison of two randomized groups within a study. 
However, synthesis method uses across-study inference, which is based on 
synthesizing analysis from multiple studies.  
 
 
2.3. Simulation  
 
 
2.3.1. Motivating example 
 
 
HER2 stands for Human Epidermal Growth Factor Receptor 2, is a member of 
the HER family. This family has four distinct receptors, the Epidermal Growth 
Factor Receptor (EGFR), HER2, HER3 and HER4. HER3/HER2 status is 
considered a potential strong covariate for Her2+ cancer as it has been shown in 
some studies that HER3+/HER2+ subjects tend to respond better than HER3-
/HER2+ patients.  
Consider a hypothetical but realistic scenario. Suppose in a historical trial, 50% 
of enrolled subjects are HER3+/HER2+, and 50% are HER3-/HER2+. In active 
controlled trial percent of enrolled subjects with HER3+/HER2+ may vary from 
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10% to 70%. We will consider four scenarios. The response rates of these four 
scenarios are as follows: 
1) Response rates of taking placebo and active control are 0.18, 0.50 for 
HER3+/HER2+ patient; response rates of taking placebo and active control are 
0.18, 0.50 for HER3-/HER2+ patient. 
2) Response rates of taking placebo and active control are 0.28, 0.60 for 
HER3+/HER2+ patient; response rates of taking placebo and active control are 
0.13, 0.45 for HER3-.HER2+ patient. 
3) Response rates of taking placebo and active control are 0.40, 0.60 for 
HER3+/HER2+ patient; response rates of taking placebo and active control are 
0.13, 0.45 for HER3-/HER2+ patient. 
4) Response rates of taking placebo and active control are 0.18, 0.78 for 
HER3+/HER2+ patient; response rates of taking placebo and active control are 
0.31, 0.38 for HER3-/HER2+ patient. 
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Figure 2.2.  Plot for response rates, HER3/HER2 status and treatment arms. 
 
 
 
Figure 2.2 describes the relationship among HER3/HER2 status, response rates 
and treatment arms. To determine whether HER3/HER2 status is a covariate, 
and to what extent it interacts with treatment arm, Table 2.1 gives numerical 
information.  
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In scenario 1, HER3/HER2 status is not associated with response rate, so it is 
not a covariate. While in scenario 2 to 4, HER3/HER2 status is associated with 
response rate, and thus it is a covariate. Moreover, in scenario 1, HER3/HER2 
status does not interact with treatment arm. In scenario 2, 3 and 4, covariate has 
mild, moderate and high interaction with treatment arm.  
If covariate is associated with the effect size of reference product, which means 
covariate interacts with treatment arm, then changes in percent of subjects with 
HER3/HER2 status will result in the constancy assumption being violated. 
Otherwise, the change in percent of subjects with HER3/HER2 status will not 
result in constancy assumption violation.
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Table 2.1. Table for association between HER3/HER2 status and outcome (column 4), and association between 
HER3/HER2 status and treatment arm (column 7). 
Scenario 
Response Rate (1:1 randomization) 
  HER3+/HER2+        HER3-/HER2+ 
Fold change of response rate 
(HER3+/HER2+ vs. HER3-/ER2+) 
Active Control vs. Placebo Odds Ratio 
 HER3+ /HER2+           HER3-/HER2+ 
Fold change of Odds Ratio  
(HER3+/HER2+ vs. HER3-/HER2+) 
1 0.34 0.34 1 4.556 4.556 1 
2 0.44 0.29 1.51 3.857 5.476 0.704 
3 0.50 0.29 1.724 2.25 5.476 0.411 
4 0.48 0.345 1.39 16.152 1.364 11.842 
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2.3.2. Simulation details 
 
 
Simulations were performed in order to evaluate and compare the operating 
characteristics of the six methods described in the previous section. The six 
methods are: 
a) Fixed Margin method (FM); 
b) Synthesis Method (Syn); 
c) Modified covariate-adjustment fixed margin method (CovFM); 
d) Modified covariate-adjustment synthesis method (CovSyn); 
e) Two-stage covariate-adjustment fixed margin method (2sFM) and; 
f) Two-stage covariate-adjustment synthesis method (2sSyn). 
In addition we will examine three different measures of association for each of 
the six methods. These three measures are: difference, log relative risk and log 
odds ratio. The log scale of relative risk and odds ratio were used because of the 
following reasons: 1) log(A/B)=log(A)-log(B)=-log(B/A). In this case, one can 
interpret the difference between A and B as the inverse of the difference between 
B and A; 2) log scale data can be approximated with Gaussian distribution 
theorem.  
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For each method and measure of association combination, 10,000 simulations 
were run to: 
1) Compare empirical type I error using target alpha level of 2.5%; 
2) Compare power using target power level of 80% at the approximate the same 
empirical alpha level;  
3)  Perform extensive sensitivity analyses to assess the performance of each 
method in lieu of violation of the constancy assumption. In particular to compare 
the degree of departure of the constancy assumption needed to double or triple 
the empirical type I error rate. Hence, this evaluation will evaluate the robustness 
of each method to deviations from the assumption used in the analysis.  
Since the null hypothesis is composite, we will measure empirical type I error rate 
when equality in null hypothesis of NI testing holds.  Power is to be compared 
when the constancy assumption holds, i.e. 50% HER3+/HER2+ in both historical 
trial and current NI trial. If the constancy assumption is seriously violated, the FM 
and Syn methods will appear to have good power. However, that is misleading 
since the type I error rate are inflated. To compare power, assign the response 
rate of test product 10 possible values, with maximum equals to the response 
rate of reference product, and minimum equals to the response rate of test 
product used in computing type I error rate. When examining the power plots, the 
type I error rates when percent of HER3+/HER2+ is 50% can be also found.  
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Simulation steps: 
(i) Use underlying true parameters to generate 1000 per arm (2 arms) in 
historical trial, 300 per arm (3 arms) in NI trial.   
(ii) Apply each of the six methods to reject/accept . 
(iii) Repeat (i) and (ii) 10,000 times, to get proportion of rejection for all six 
methods and three measures of association. 
 
2.3.3. Simulation results 
 
 
For each scenario and measure of association combination, results are 
presented in a panel of four plots in one figure. Row one presents the type I error 
rate while row two presents the power. Column one gives results over broad 
range of all values while column two zooms in on values of interest. The upper 
left plot has 7 groups of points for each of the six methods (corresponding to 
percent of HER3+/HER2+ in NI ranging from 10% to 70% by 10% increments). 
Note that 50% is the same percent of HER3+/HER2+ in historical trial, so points 
around it (40%, 50% and 60% of HER3+/HER2+ in NI trial) are zoomed, which 
are shown on the upper right.  The bottom left plot is 10 groups of points for each 
of the six methods (corresponding to 10 points between ranges of possible test 
product effect). Note that the 10th group of points is the power when test product 
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effect equals to that computed in type I error rate. So they are actually type I 
error rate when the percentage of HER3+/HER2+ is 50% in NI trial. Closer look 
at power around the type I error rate are shown on the bottom right plot.  
This section will only show the results for scenario 2 (mild interaction) only since 
the conclusions drawn from scenario 2 also hold for the other three scenarios. To 
see simulation results for scenario 1, 3 and 4, please refer to Appendix A.   
 
Scenario 2:  
Response rates of placebo and active control treatment groups are 0.28, 0.60 for 
HER3+/HER2+ patients; response rates of placebo and active control treatment 
groups are 0.13, 0.45 for HER3-.HER2+ patients. 
In this scenario, HER3/HER2 status is a covariate. This covariate does not 
interact with treatment arm using metric difference, but mildly interacts with 
treatment arm using metrics log relative risk (LRR) and log odds ratio (LOR). 
Thus change of percent of HER3+/HER2+ in NI will not cause constancy 
assumption violation for metric difference, but will result in constancy assumption 
violation for LRR and LOR. 
Plots for type I error rate and power, using three measures of association 
(difference, log relative risk and log odds ratio) are shown in Figure 2.3, Figure 
2.4 and Figure 2.5.  
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Figure 2.3.  Performance Characteristics Comparisons--Measure of Association: 
Difference. 
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Figure 2.4.  Performance Characteristics Comparisons--Measure of Association: 
Log Relative Risk. 
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Figure 2.5.  Performance Characteristics Comparisons--Measure of Association: 
Log Odds Ratio. 
 
 
When using LRR and LOR, increasing the percent of HER3+/HER2+ will 
decrease the effect of reference product over putative placebo, and also 
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decrease the effect of reference product over test product. Thus the 10% point 
corresponding to the biggest “Treatment effect of RP over Putative Placebo” in 
type I error plots in Figure 2.4 and 2.5.  
Type I error rates of FM, CovFM and s2FM are all under 0.025, while Syn, 
CovSyn and 2sSyn have higher type I error rates and can be greater than 0.025 
at some points. As can be seen in Figure 2.4 and 2.5, even slight departure from 
the constancy assumption (50%) causes the type I error rate inflated. Looking at 
upper left plots in Figures 2.3, 2.4 and 2.5: type I error rates of CovSym and 
2sSyn are larger than 0.025 when constancy assumption holds (note this is the 
case where we adjusted the covariate when it is unnecessary). As can be seen in 
upper right plots of Figures 2.4 and 2.5, the synthesis method is extremely 
sensitive to constancy assumption such that any small departure from constancy 
assumption, and/or any small estimation variation inflates the type I error rate. 
The fixed margin method is more stable in controlling the type I error rate. 
CovFM and 2sFM improve the conservativeness of FM, but can still control type I 
error rate at target value 0.025.  
Note the reason that we only see type I error rate inflated in one direction is 
because the bigger the relative effect of reference product over placebo, the 
bigger is the relative effect of reference product over test product. Thus it will 
make it harder for us to reject the null hypothesis of NI.  
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Figures 2.3, 2.4 and 2.5 Power plots show that CovFM has higher power than 
both 2sFM and FM. CovFM  has similar operating characteristics across all 
scenarios, even when there is no interaction effect (Figure 2.3). As expected 
2sFM has larger power than FM since 2sFM rejects the null hypothesis in (6) 
when there is a strong observed covariate effect and therefore will use CovFM, 
which is a model-based regression approach. However 2sFM has less power 
than CovFM because of potential type II error associated with testing hypothesis 
(6), i.e. fail to reject the null hypothesis in (6) even though the covariate effect is 
warranted.  
Table 2.2 summarizes the type I error rates of the six NI methods, for different 
percentage of HER3+/HER2+ (10% to 70% by 10% increment) using three 
different measures of associations (difference, LRR, and LOR). Bold rows are 
percents of HER3+/HER2+ 40%, 50% and 60%. Table 2.3 summarizes the 
power of the six NI methods, when 50% of HER3+/HER2+ population in NI trial. 
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Table 2.2. Scenario 2-- Type I Error Rate   
 
Metric Perc_HER3+/HER2+ P T C FM Syn CovFM CovSyn 2sFM 2sSyn 
Difference 
0.1 0.145 0.305 0.465 0.0085 0.0279 0.0082 0.0295 0.0085 0.0283 
0.2 0.16 0.32 0.48 0.0084 0.0251 0.0087 0.0297 0.0084 0.0278 
0.3 0.175 0.335 0.495 0.0083 0.0241 0.0105 0.0303 0.0095 0.0285 
0.4 0.19 0.35 0.51 0.007 0.0228 0.0106 0.033 0.0096 0.0293 
0.5 0.205 0.365 0.525 0.0086 0.0253 0.0129 0.0347 0.0115 0.0306 
0.6 0.22 0.38 0.54 0.007 0.0222 0.0093 0.0303 0.0083 0.0273 
0.7 0.235 0.395 0.555 0.009 0.0244 0.0114 0.0323 0.0101 0.029 
LRR 
0.1 0.145 0.259663 0.465 3.00E-04 0.0015 0.0053 0.0357 0.0019 0.0152 
0.2 0.16 0.277128 0.48 0.001 0.0042 0.0087 0.0407 0.0042 0.0255 
0.3 0.175 0.294321 0.495 0.0016 0.0075 0.0083 0.044 0.0057 0.031 
0.4 0.19 0.311288 0.51 0.0035 0.0158 0.0125 0.0478 0.0089 0.0356 
0.5 0.205 0.328062 0.525 0.0063 0.0245 0.0124 0.0464 0.0104 0.0394 
0.6 0.22 0.344674 0.54 0.0123 0.0397 0.0145 0.043 0.014 0.0418 
0.7 0.235 0.361144 0.555 0.0185 0.0659 0.0107 0.0446 0.0135 0.0519 
LOR 
0.1 0.145 0.277419 0.465 0.0023 0.008 0.0083 0.0322 0.0048 0.016 
0.2 0.16 0.295434 0.48 0.0021 0.0104 0.0087 0.0369 0.0045 0.0258 
0.3 0.175 0.313179 0.495 0.0042 0.0159 0.0102 0.0392 0.0078 0.0311 
0.4 0.19 0.330704 0.51 0.0055 0.0187 0.0113 0.0376 0.0097 0.0301 
0.5 0.205 0.348049 0.525 0.0071 0.0239 0.0119 0.0387 0.0107 0.0316 
0.6 0.22 0.365247 0.54 0.0083 0.0289 0.0112 0.0388 0.0103 0.0352 
0.7 0.235 0.382323 0.555 0.0112 0.0351 0.0106 0.0356 0.0107 0.0362 
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Table 2.3. Scenario 2--Power  
Metric P T C FM Syn CovFM CovSyn 2sFM 2sSyn 
Difference 0.205 0.507222 0.525 0.8424 0.9244 0.8742 0.9433 0.8628 0.9353 
LRR 0.205 0.503118 0.525 0.9898 0.9978 0.9951 0.9989 0.9938 0.9986 
LOR 0.205 0.505339 0.525 0.9132 0.968 0.937 0.9801 0.928 0.9751 
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2.4. Conclusions and discussion 
 
 
Both FM and Syn have inflated type I error rate when constancy assumption is 
seriously violated (scenario 4 as shown in Appendix A), Syn is the more liberal of 
the two. Syn is also very sensitive to violations of the constancy assumption. 
Small departure from constancy assumption, and/or small estimation variation 
could inflate the type I error rate. While not as severe as Syn, both the CovSyn 
and 2sSyn methods also have inflated type I error rates due to sensitivity of Syn.    
FM has empirical type I error rate over the desired value when constancy 
assumption is seriously violated, although it is not as sensitive as the Syn 
method. This can be explained mathematically: from the formula     ! "
#.QT$%&  1  U'(  )  #.QT$*&+ , if constancy is seriously violated,  ( ) will become smaller, and so it is easier to reject the null hypothesis, resulting 
in inflated type I error rate. When constancy assumption does not hold due to 
covariate effect, adjusting for this effect will result in significantly less type I error. 
This is why the CovFM and 2sFM methods perform better than FM method in 
controlling the type I error rate. 2sFM may falsely accept the null hypothesis in 
(6). Method CovFM performs consistently well across all scenarios: CovFM 
method has almost the same power as 2sFM in scenario 1 (no covariate no 
interaction) and scenario 4 (covariate and high interaction), while CovFM has 
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larger power than 2sFM in scenario 2 (mild interaction) and scenario 3 (moderate 
interaction).   
Based on these results we recommend using CovFM (modified covariate-
adjustment fixed margin method) since it controls the type I error rate and has 
satisfactory power for any of the three measures of association.  
The most logical use for this methodology is when a company wants to show NI 
for a new formulation, for example, a new Sub Q dose for the company’s existing 
IV drug. Thus the company has individual patient data. It is our hope that with the 
emphasis on comparative effectiveness initiatively found in the Affordable Care 
Act passed by the US Congress on March 23, 2010 that sharing individual 
patient data among sponsors/agencies will be possible in the future.  
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3.  Inference of Bioequivalence for log-normal distributed data with 
unspecified variances (Second Topic) 
 
 
 
3.1. Introduction 
 
 
Establishment of bioequivalence (BE) is a regulatory requirement needed prior to 
claiming that a proposed generic version (test product) of a drug is equivalent to 
the branded-name drug (reference product). For example, U.S. FDA guidance 
document [17] recommends that 90% confidence interval (CI) values for the ratio 
of the relative means for AUC0-t, AUC0-∞, and Cmax of the new and reference 
drugs should fall between 0.80 and 1.25. These limits, set by regulations 
applicable in both U.S. and the European Economic Area, are acceptance criteria 
to assure that the difference between the test and reference products is no more 
than clinical relevance. AUC and Cmax are two pharmacokinetic (PK) 
parameters that represent area under the concentration-time curve and 
maximum concentration of a drug. The usual BE definition places the focus of 
statistical inference on whether the parameter of interest falls within the 
equivalence margins even more rigorously than estimating the parameter itself.  
Since the distribution of PK data is often assumed to be log-normal, BE is 
assessed on the difference in a logarithm-transformed PK parameter.  
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   Statistical methods in establishing BE are readily available in literature 
including testing procedures developed by Metzler [34], Kirkwood [29], Westlake 
[3], Anderson and Hauck [1], Locke [32], Schuirmann [43], Berger and Hsu [53], 
among others. A comparison of operating characteristics in these testing 
procedures can be found in a review paper by Choi et al. [11]. The above 
methods are based on frequentist theory. One short fall of the frequentist theory 
is it attempts to use the same probabilities to measure both the chance of errors 
and the strength of evidence (Royall, [38, 39]). In [11], the authors proposed the 
use of a likelihood method by visually analyzing a standardized likelihood plot 
[38, 39]. This has generated interest in whether statistical evidence using a 
likelihood method can be used as an alternative or supplement to the usual 
practice of decision making based on testing procedures in BE setting. 
   When inference about BE based on the difference () is of interest and the true 
variances (σQ) is unknown, the traditional solutions involve replacing or removing 
σQ out of the analysis model. For instance, the hypothesis testing by the two one-
sided tests (TOST) uses sample estimates for the σQ, Bayesian method handles 
this by integrating out σQ over some non-informative prior. Since σQ is either 
replaced or removed, it raises a concern that these current analysis methods 
conceal the extent to which inference about  is affected by σQ [7].  
   In this topic, we propose a likelihood approach that retains the unspecified 
variances in the model via three parameters: the ratio of two variances (LQ), the 
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variance of the reference drug $VQ, and correlation of the two drugs (W) for cross-
over studies only. “Unspecified” means those parameters are included in the 
model and allowed to vary over a range of values, to show the robustness of BE 
inference conditional on different values. We expand the likelihood approach for 
the ratio of two normal means by Diaz-Frances and Sprott [14] to address 
average bioequivalence of log-normal data by expressing the entire likelihood 
function in the product of two components:  a function of F-statistic for variances 
and the a function of the t-statistic for . The proposed method helps identify 
ranges of the unspecified variances where BE is more likely to be achieved, 
which cannot be accomplished by methods that replace or remove these 
parameters. The proposed method addresses both cross-over and parallel 
designs.  
   The likelihood approach is specifically chosen for its focus on showing strength 
of evidence using data, which is consistent with our aim on generating evidence 
and measuring the extent that BE is affected by the unspecified variances. On 
the other hand, testing procedures such as TOST are only interested in whether 
the data support the nonequivalence or the equivalence hypothesis. Bayesian 
analysis presents a posterior probability distribution of , which is determined by 
the prior probability distribution of  and likelihood function (probability model for 
the observed data). It focuses on inference in  changing from prior, through 
observed data (via likelihood function) to posterior. We derived a Bayesian 
probability distribution using the method by Rubio and Perez-Elizalda [40] to 
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address our specific problem. It can be used to describe the probability that  
falls within the BE margins. The proposed method is compared with TOST and 
Bayesian method using published data. 
    The remainder of this whole part is organized as follows. Section 3.2 describes 
the proposed likelihood method. Section 3.3 presents the Bayesian model 
applicable to our specific question. The impact on BE by the unspecified 
variances is described in section 3.4. Comparison of different methods will be 
shown in section 3.5. Last section 3.6 is summary.  
 
 
 
3.2. The Likelihood Method 
 
 
3.2.1. Crossover Design 
 
  
Suppose two variables XY 
 log XYI and ]Y 
 log ]YI, C 
 1, … , _, that represent 
log-transformed individual observations of a PK parameter (AUC or Cmax) for 
the two drugs, follow bivariate normal distribution (BVN): 
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`XY 
 log XYI]Y 
 log ]YIa ~cde f` " gg a , `LQ$Q WL$QWL$Q $Q ah                             (1) 
For simplicity, we focus on log(AUC) (log(ij%, log(ijV), T=test, R=reference) 
throughout this section, the implication of log(Cmax) follows similarly. Parameters 
in (1) represent  
 klogij%  klogijV)), g= klogijV)) and LQ the 
ratio of two variances (LQ 
 $%Q/$VQ) and $Q 
 $VQ (Note log() means general 
logarithm, ln() means natural logarithm). The correlation coefficient W is to 
address cross-over designs where subjects start with one drug and then are 
switched to the other drug usually after a wash-out period, as such XY and ]Y are 
observations from the same subject, while in parallel designs W=0. Model (1) 
assumes there is no sequence or period effect.  
   The equivalence hypotheses with the pre-specified margins of mn=ln(0.8)o-
0.223 (natural logarithm) and mp=ln(1.25)o0.223, can be stated as 
                                         :  q mn or Q:   mp 
 R:  r mn and  RQ:   mp                                          (2) 
Schuirmann’s TOST [43] can be used to test the hypothesis in (2). By rejecting 
the pair of null hypotheses  and Q, equivalence can be declared if and only 
if: 
                                  n r D5s,t5 and   p  D5s,t5 
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where  n 
 uv5wM5xy9z{|}~| ,  p 
 uv5wM5x9z{|}~| , Xv 
 ∑ ut , and ]M 
 ∑ wt , D5s,t5 is the (1 
?)-th percentile of the Student’s t-distribution with n-1 degrees of freedom.  
   The likelihood approach focuses on showing the statistical evidence instead of 
making decision to choose between equivalence and nonequivalence. The 
likelihood function based on model (1) is in the form of 
 , g, W, L, $| K, F  9<5</< X  Q9<5< i                      (3) 
where i 
 {< " w " tuv55<< " _]M  gQ  Q ∑ XY    g]Y  gtY  
 u 
 ∑ XY  XvQtY  and w 
 ∑ ]Y  ]MQtY . 
Without the knowledge of true g and $, a likelihood function of , L and W can be 
constructed by replacing g in (3) with its restricted maximum likelihood estimator 
(rMLE) ĝ, L, W 
 5uv=5wM555Q=< , followed by replacing $Q with its 
rMLE $Q 
 Qt5< where B={< " w " tuv5wM5<5<5Q=<  Q uw and uw 

∑ XY  Xv]Y  ]MtY . That is  
 Ru, W, L|K, F  5<< {< " w " tuv5wM5<5<5Q=<  Q uw5t               (4) 
Following some algebra, the function in (4) can be subsequently partitioned into 
two parts: 
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Ru, W, L|K, F 
 W, L  |W, L                            (5) 
where 
 W, L  ` ~5<at                                           (6) 
|W, L  1 " <Qt5Q5t                                        (7)  
 
  {¡<=~5<¢¡ {~Q~5< , DQ 
 `uv5wM59z{|}~| aQ 
 uv5wM5<E}<¢¡£¡<G 9z<, and $Q 
 
 {¡<=~5<¢¡ {~Qt55< .   
Derivation of (3)-(7) is outlined in Appendix A. Taking  
 mn and  
 mp the 
corresponding D in (7) equal to  n and  p respectively. This means |W, L in 
(7) can produce the results of TOST and more importantly the likelihood function 
in (5) which is the product of (6) and (7), will provide no less information than 
TOST alone on the inference about BE.  
 
 
3.2.2. Parallel Design 
  
 
In a parallel design, the distribution of XY , C 
 1, … , _, and ]¤ , ¥ 
 1, … , ¦ can be 
referred to (1) with W 
 0. The corresponding maximum likelihood function can be 
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obtained by replacing g and $Q by their rMLEs ĝ, L 
 tuv5=<wMt=<  and 
$Q 
 t= with B={< " w " tuv5wM5<t=< ,  
   Ru, L|K, F 
 L  |L                               (8) 
where 
L  /Q§_  1 " ¦  1¨5t=/Q                          (9) 
|L  1 " <t=5Q5£©<                                 (10) 
 
 ~/ª59<«{/§t5<9<¨ 
 t5~<5{ , DQ 
 t·uv5wM5<<=t9z< , and $Q 
  {¡<=~=t5Q.   
By taking  
 mn and  
 mp, the corresponding D in (10) equal to  n and  p 
respectively. 
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3.3. Bayesian approach 
 
 
3.3.1. Crossover Design 
 
To help derive the Bayesian posterior distribution a change of parameters will be 
needed. Rather than using (1) we employ the following form of distribution for XY 
and ]Y (which bears no deviation from the distribution (1) and its likelihood 
function (3))  
`XY 
 log XYI]Y 
 log ]YIa ~cde fgg  , `LQ$Q WL$QWL$Q $Q ah                     (11) 
The density function is in the form of 
¬XY, ]Y)= Q­9<5< X ® Q5< u5<<9< " w5<9<  Qu5w59< ¯ 
The likelihood function for g, g, L, $, °_± W can be expressed as 
  g, g, L, $, W| K, F  9<5</< X  Q9<5<                  (12) 
where  
 {< " w " tuv5<< " _]M  gQ  Q ∑ XY  g]Y  gtY , u and w 
follow (3).  
A suitable reference prior was suggested by Berger and Sun [44]  
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  ²V³g, g, L, $, W  <9´5<<´ 
 $5µL5Q1  WQ5<´                                                                           
Using this prior, the posterior density of the parameters (g, g, L, $, W) is in the 
form of  
 ² g, g, L, $, W|K, F   L5t5Q$5Qt5µ1  WQ5<5<´X  Q9<5<          (13) 
where C is defined in (12).  
After some algebra and integrating out parameters other than , the marginal 
posterior distribution of  originated from (13) can be presented in the following 
form  
², |K, F    ¶ ¶ ·}< 1  ·}< 1  WQ }< ª1  2W1  ··«5 · ¸·, WQ "5
1−·ux−−y2"4W21−··X−y−W21−··x−"y21−2W1−··−_·1−D,·,W2  ±·±W      (14) 
where D, ·, W is the student’s t-distribution function with _ degrees of 
freedom evaluated at D, ·, W. Derivation of (14) along with the expression of 
D, ·, W is shown in Appendix C.  
 
3.3.2. Parallel Design 
 
 
In parallel designs, the distribution of XY , C 
 1, … , _; ]¤ , ¥ 
 1, … , ¦ can be referred 
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to (11) with W=0, the likelihood function of g, g, L, °_± $ follows  
L g, g, L, $| K, F  9£© X  Q9< ¾                                (15) 
where ¾ 
 ∑ u5< < " ∑ E]¤  gGQ¤ 
 {< " w " tuv5<< " ¦]M  gQ 
A suitable prior distribution as suggested in [44] is in the form of 
²V³g, g, L, $  1LQ$µ 
 $5µL5Q 
Then the posterior density function of parameters (g, g, L, $) can be expressed 
as  
  ² g, g, L, $|K, F   L5t5Q$5t=5µX  Q9< ¾                  (16) 
After some algebra and integrating out parameters other than , the marginal 
posterior distribution of  originated from (16) can be expressed as:   
²|K, F  ¶ ·©}< 1  ·}< §·Q " 1  ··xM    yMQ¨5£©£< · §1 D,·  ±·                                                                                                      (17) 
Where D, · is the student’s t-distribution function with (_ " ¦ " 1 degrees 
of freedom evaluated at 
D, · 
 ¿ _ " ¦ " 1·Q " 1  ··xM    yMQ · '§1  ·Xv   " ·]M¨+ 
Derivation of (17) follows similarly to that of (14).   
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3.4. Inference on BE affected by unspecified variances 
 
In this section, we illustrate the proposed likelihood method, using data from a 
published crossover study, to assess the impact of unspecified variances on the 
inference about BE. The unspecified variances are characterized by LQ (the ratio 
of two variances), $ÀQ (variance for the reference drug) and W (correlation 
coefficient). To do so, we construct a likelihood function of  by retaining these 
three parameters in the function (5). 
 
3.4.1. A log-normal data set and TOST result  
 
 
Data in Example 1 came from the published crossover BE study by Marzo et al. 
[33]. 
Test drug ln(AUC0-t):  {7.89, 6.53, 6.48, 6.62, 7.93, 6.99, 6.14, 6.78, 6.89, 7.43, 
6.52, 6.78, 5.56, 6.84, 7.04, 6.52, 6.70, 6.63, 6.29, 6.41, 5.88, 6.25, 6.92, 7.23}. 
Reference drug ln(AUC0-t):  {7.61, 6.80, 6.61, 6.16, 7.83, 6.94, 5.45, 6.45, 6.94, 
7.08, 6.39, 6.71, 5.22, 6.68, 6.88, 6.32, 6.85, 6.75, 6.38, 6.86, 6.44, 5.96, 7.06, 
6.97}. 
The study compared a new formulation of ticlopidine hydrochloride (test) to the 
reference Tiklid (marketed drug). Ticlopidine hydrochloride is an inhibitor of 
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platelet aggregation used in the management and prevention of thromboembolic 
disorders. Using the notations in 3.2.1, the observed mean values of ln(AUC) are 
Xv=6.72 and ]M=6.64 for test and reference respectively; u=6.94, w=7.64 and 
uw=6.34, and correlation is W =0.870. Results of TOST using SAS© 9.2, PROC 
T-Test Procedure are summarized in Table 3.1. 
 
Table 3.1. TOST results, confidence intervals and equivalence assessments for 
Examples 1 and 2 data  
 
 
Example 1 Example 2 
N 
 
24 12 
Mean: Xv  ]M 
 
0.0796 0.0417 
95% CI Mean 
 
(-0.0421, 0.2013) (-0.2888, 0.3721) 
90% CI Mean 
 
(-0.0213, 0.1804) (-0.2280, 0.3113) 
SD 
 
0.2883 0.5201 
95% CI SD 
 
(0.2240, 0.4044) (0.3685, 0.8831) 
TOST (?=0.05) 
 
  
p-value (upper) 
 
<.0001 0.0528 
p-value (lower) 
 
0.0114 0.1261 
p-value (overall) 
 
0.0114 0.1261 
Assessment 
 
Equivalent Not equivalent 
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The 90% CI of =Xv  ]M is (-0.0213, 0.1804) which falls within the equivalence 
margins (-0.223, 0.223), and overall p-value, p=0.0114 is significant at 0.05 level. 
These results clearly suggest rejection of the null hypothesis in (2).  
 
3.4.2. Standardized profile likelihood (SPL) 
 
 
Figure 3.1 shows the plot of the standardized profile likelihood (SPL) for 
Ru, W, L|K, F of  as shown in (5) with L=0.953 and W=0.87 (sample 
estimates) and  in the range of (-0.4, 0.4). The standardization was taken to 
have the maximum value of 1 for the vertical scale of the plot: 
SPL=Ru|K, F, W 
 .87, L 
 .953/Ru 
 Xv  ]M|K, F, W 
 .87, L 
 .953 and 
because both W and L are specified, the component W, L in (5) is cancelled 
out in SPL. According to [38], SPL=1/8 and 1/32 are two common reference lines, 
values that fall into the likelihood interval (LI) corresponding to SPL=1/8 and 1/32 
(namely 1/8 LI and 1/32 LI) indicate “moderate strong” and “strong” evidence 
supported by the data, respectively. Two vertical solid lines represent BE 
margins -0.223 and 0.223. The horizontal dashed line, SPL=0.226 was obtained 
by inserting one-sided critical value of t distribution, t(0.95,23)=1.714 into SPL. 
The two points on the SPL curve intersecting with SPL=0.226 are -0.0213 and 
0.1804, yielding the same two limits of the 90% CI using TOST shown in Table 
3.1. To avoid the confusion with traditional CIs, we name these two limits on the 
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SPL curve as SPL CI, and SPL CI with t(0.95,df) as 90% SCI. Hence, with L and 
W taking values given above, the (1-2?)% SCI matches the (1-2?)% CI using 
TOST. This can be proven by letting DQ 
 `uv5wM59z{|}~| aQ 
 DQ(1-?,Å) in (7), which 
results in ,Q (on SPL) = Xv  ]M Æ D(1-?,Å)Ç $uv5wM.  
   In Figure 3.1, the 90% SCI, 95% SCI and 1/8 LI are all comprised within the BE 
margins, though 1/32 LI does not, suggesting the evidence is somewhere 
between moderate to strong in favor of BE. Note that 1/8 LI is very close to 95% 
SCI (and hence 95% CI), which is expected as Royall [38] showed for normally 
distributed random variables that1/8 and 1/32 LIs are approximately the same as 
the 95% and 99% CIs, though 1/32 LI appears to be excessive in the BE setting.  
Note that the width of (1-2?)% SCI equaling to w=2 D(1-?,Å)Ç $uv5wM, is proportion 
to $uv5wM and according to (7) contains the parameters L and W. We use contour 
plots to characterize how widths of 90% and 95% SCIs are related to L and W. 
Figure 3.2 shows the contour plots of widths of SCIs using Example 1 data, in 
terms of L and W. The solid thick line represents the width of 90% SCI=0.2013 
(on left panel) and 95% SCI =0.2435 (on right panel) which are both narrower 
than the width of the BE margins (o0.446). With L=0.953, W= 0.87 and $uv5wM = 
0.0588 the data suggest adequate evidences of equivalence. Given that there 
are a range of pairs of L and W associated with the same width of a SCI, it should 
help identify the source of the variability either due to heterogeneity, weak 
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correlation or large variances of the two samples that could reduce the probability 
in achieving BE. 
 
Figure 3.1. Plot of SPL of Delta for Example 1 data 
 
Figure 3.2. Contour plots for the widths of 90% and 95% SCIs for Example 1 
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3.4.3. Inference about BE affected by L 
 
 
In this section, we show the impact unspecified variances have on BE inference. 
To do so, we retain L in the likelihood function (4) but replace W with its sample 
estimate W =0.87. The use of the sample estimate for W allows us to explore how 
inference about BE (based on ) can be affected by L. The distances between 
the upper and lower margins are considered in demonstrating the sensitivities of 
the inferences to L. Sample estimator L = u/w=0.953 is chosen as the base 
value. Alternative values of L can be obtained by certain confidence intervals or 
other meaningful justification. Figure 3.3 presents ratios of L at its alternative 
values against its base value (note that a reciprocal value is taken if ratio is less 
than 1). It also shows the ratios of lengths between the upper and lower margins 
observed at the alternative over the base value of L. The ratios of lengths are 
presented at three levels of SPL, those corresponding to 90% and 95% 
confidence intervals (SCIs) and those at 1/8 LI.   
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Figure 3.3. Ratios of gamma and length of margin at the alternative values 
against base value 
  
 
Figure 3.3 shows the ratios of the margin lengths are almost proportional to the 
ratios of L′s. Moreover, the ratios of margin lengths, and therefore the 
sensitivities, are independent of the level of SPL. An exact calculation based on 
(8) gives us a range of L where BE is achieved using Example 1 data is 0.670q
L q1.439 at 90% SCI level. The 90% SCI when L=0.670 or L=1.439 is (-0.064, 
0.223). But in either case, the variances of the two drugs are no longer 
homogeneous raising concerns that one of the drugs carries more variability in 
rate of absorption than the other one, even though the 90% SCI is still within the 
BE margins.  
Analysis of BE by TOST use sample estimate so that test statistics follows 
student t-distribution. It conceals the extent to which inference about BE is 
affected by L, which was also noted in [7]. Moreover, when analyzing BE data 
using TOST, it’s not uncommon that variances of two groups are pooled 
0.5
1
1.5
2
2.5
3
3.5
4
Gamma SCI95 SCI90 LI 1/8
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regardless whether they are homogeneous. As indicated by Hua et al. [22] the 
control of type I error rate may be inflated when pooling of two variances is 
unjustifiable. We believe that, in the presence of unspecified variances and the 
extent of heterogeneity is a concern, the proposed model Ru, W, L|K, F (5) 
could help determine a range of L where BE is more likely to be achieved.    
 
3.4.4. Inference about BE affected by σ  
 
 
When LQ is a known constant (e.g. LQ=ÈQ), unspecified variances can be 
represented by the reference drug $Q ($VQ=$Q). Again the distances between the 
upper and lower margins are considered in demonstrating the sensitivities of the 
inferences to $. Sample estimator $ 
0.56 is chosen as the base value. 
Alternative values of $ can be obtained by confidence intervals or other 
meaningful justification. Figure 3.4 presents the sensitivities of the inferences to 
$. The figure shows the ratios of $ at its alternative values against its base value 
(take reciprocal if ratio is less than 1), and also the ratios of the lengths between 
the upper and lower margins observed at the alternative over the base value. 
Again, the ratios of lengths are presented at three levels of SPL: those 
corresponding to 90% and 95% confidence intervals (SCI) and those at 1/8 LI. 
Since the width of length is proportional to $, the ratio of $ at alternative values 
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and the corresponding ratios at three levels of SPLs are constant, as shown 
below. 
 
Figure 3.4. Ratios of sigma and length of margin at the alternative values against 
base value 
 
 
The range of $ where BE is more likely to be achieved for Example 1 data is 
$ q0.817, with 90% SCI (-0.064, 0.223).  
Since coefficient of variation (CV) of the original scale and $ of the natural log-
transformed data follow dQ 
 exp$Q  1, the impact (on BE) by a large $ in 
log-transformed data is synonymous to a large CV in original scale. Thus in the 
presence of unspecified variances and the extent of CV is a concern, the 
proposed model Ru, W, L|K, F (5) could help determine a range of $ where 
BE is more likely to be achieved.    
1
1.5
2
2.5
3
3.5
4
Sigma SCI95 SCI90 LI 1/8 
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3.4.5 Inference about BE affected by ρ 
 
 
Following the approach in the two previous sections, sample estimator W = 0.87 
is the base value. Figure 3.5 shows the sensitivities of the inferences to W. The 
figure presents the ratios of W at its alternative values against its base value (take 
reciprocal if ratio is less than 1), and also presents the ratios of the lengths 
between the upper and lower margins observed at the alternative over the base 
value of W. Again the ratios of lengths are presented at three levels of SPL, those 
corresponding to 90% and 95% confidence intervals (SCIs) and those at 1/8 LI. 
The sensitivity relationship between margin length and ρ is, understandably, 
more complicated. An exact calculation gives the range of W where BE is more 
likely to be achieved is W 0.648 for Example 1. The 90% SCI margin for 
W=0.648 is (-0.064, 0.223).  
Figure 3.5. Ratios of rho and length of margin at the alternative values against 
base value 
 
1
2
3
4
5
Rho SCI95 SCI90 LI 1/8
  
 
58
3.5. Comparison of Different Approaches in Crossover Design   
 
 
In this section, we compare results based on the proposed likelihood, TOST, and 
Bayesian approaches using two data sets. Example 1 was presented in Section 
3.4.1, additional descriptive statistics include L=0.953, W= 0.87, u/_ =0.538, 
w/_  =0.564 and  $uv5wM = 0.0588. 
Example 2 is also a crossover BE data with 
Test drug XY: {7.85, 4.77, 6.81, 6.64, 6.59, 7.81, 8.07, 7.92, 8.09, 7.11, 7.76, 
6.95},  
Reference drug ]Y: {8.30, 5.35, 6.35, 6.70, 6.57, 6.57, 7.47, 7.91, 8.45, 7.57, 
7.72, 6.91}. 
Data (ln(AUC) only) were presented in Balthasar [2] from a simulated 
cyclosporine bioequivalence study with 12 subjects, for a two-treatment, 
crossover study of 300mg of cyclosporine administered orally. Data were 
simulated assuming the same parameter values and variances for both study 
periods; consequently, there was no ‘true’ difference between the formulations on 
their rate and extent of absorption. However, these parameter values lead to 
moderately high values of intra-subject variability in AUC. In addition to 
descriptive statistics presented in Table 3.1, Xv  ]M=0.0417, L=1.053, W=0.844, 
u/_ =0.912, w/_ =0.866 and $uv5wM=0.150. The contour plots for the widths of 
  
 
59
90% and 95% SCIs using Example 2 data is shown in Figure 3.6. The solid thick 
line represents the width of 90% SCI =0.5393 (on the left panel) and 95% SCI 
=0.6609 (on the right panel), which are larger than the distance of the standard 
BE margins (0.446). It represents failing to achieve BE for the two drugs based 
on the standard BE criteria. On the other hand, this example represents a class 
of drugs with high variability, for which a widened equivalence margins (e.g. 
ln(0.7) and ln(1/0.7)) are often considered appropriate. The implications of the 
three parameters (L, $, °_± W), and their impact on BE follows similarly to those 
discussed for Example 1.  
 
Figure 3.6. Contour plots for the widths of 90% and 95% SCIs for Example 2 
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TOST results  
Results in Table 3.1 suggest that equivalence in ln(AUC) is achieved for Example 
1 and failed for Example 2.  
 
Proposed likelihood functions of Ë (5) and (7) with Ì replaced by its sample 
estimate 
Table 3.2 shows the SPL CIs of the likelihood functions in (5) and in (7) with L 
and W replaced with the sample estimate. In both examples, the SPL CIs 90% 
and 95% SCIs are nearly identical results to the 90% and 95% CIs of the 
difference =Xv% – XvV generated using the TOST method (Table 3.1), which 
according to Sec 3.4.2, is theoretically correct.   
 
Table 3.2. Results of Profile Likelihood and Fieller Pivotal 
Data set SPL at  t(0.95, df) SPL CI 
SPL at  
t(0.975, df) SPL CI 
Example 
1 SPL=0.226 
Likelihood in (5) 
-0.0213, 0.180 
Likelihood in (7)  
-0.0213, 0.180 
SPL=0.118 
Likelihood in (5)  
-0.0421, 0.2013 
Likelihood in (7)  
-0.0422, 0.2013 
Example 
2 SPL=0.194 
 
Likelihood in (5)  
-0.223, 0.3113 
Likelihood in (7)  
-0.228, 0.3113 
 
SPL=0.0918 
Likelihood in (5)  
-0.2888, 0.3721 
Likelihood in (7) 
-0.2888, 0.3721 
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Bayesian analysis with Ì, Í, Î integrated out 
Table 3.3 presents the Bayesian analysis results based on the marginal posterior 
distribution of  provided in (14). The highest posterior density (HPD) interval is 
frequently referred to as the shortest Bayesian credible interval that satisfies the 
following two conditions: i) the posterior probability of that set is 100(1-?)%, ii) the 
minimum density of any point within that set is equal to or larger than the density 
of any point outside that set [10]. The results in Tables 3.3 include 90% and 95% 
HPDs and the probability of posterior distribution of  falling within the 
equivalence margins (-0.223, 0.223) for each example. Posterior density of  is 
plotted and shown in Figure 3.7 for the two examples. Results in Table 3.3 
suggest that posterior distribution of   yield lightly wider HPD intervals relative to 
the corresponding SPL CIs using the proposed likelihood method (Table 3.2) or 
the CIs produced by the TOST method (Table 3.1).      
 
Table 3.3. Results of Bayesian Analysis 
Data set 90% HPD 95% HPD 
Prob of  falls 
within 
(-0.223, 0.223) 
Example 1 -0.0232, 0.1823 -0.0445, 0.2036 0.9873 
Example 2 -0.2381, 0.3214 -0.3016, 0.3850 0.8072 
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Figure 3.7. Bayesian Posterior Density for Two Examples 
 
Comparison 
This section along with results in Sec 3.4.1 suggest that CIs of  generated by 
TOST can be matched exactly with those SPL CIs generated by the likelihood 
function in (5) or in (7) with L and W replaced with sample estimate. This suggests 
that likelihood functions (5) and (7) will provide the same information about  in 
general case. In the special case where L and W may also contain information 
about , then SPL CIs of  generated by (5) will be narrower than that by (7) 
because W, L in (6) is dependent on . This point is demonstrated in a ready 
to submit paper by the same authors. The Bayesian HPD intervals of  
generated from (14) are slightly wider than CIs generated by TOST, and SPL CIs 
using the likelihood function (5) or (7). On the other hand, Bayesian approach 
does not overcome the drawback that it conceals the extent to which inference 
on BE is affected by L, W or $.  
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3.6. Conclusions and future direction 
 
 
We believe that when it comes to establish BE, one should look beyond just 
relying on simple hypothesis testing to reach a final conclusion. The proposed 
likelihood method that measures and presents strength of evidence from the data 
offers more information than just relying on simple hypothesis testing to reach a 
final conclusion on BE, even though TOST are the most commonly used decision 
making tools. The proposed method addresses the inadequacy of hypothesis 
testing by including the parameter m (i.e., LQ, $VQ|LQ 
 È or W) to represent 
unspecified variances. This enables us to assess the extent that BE is affected 
by the variability of PK parameter m, i.e. assess the robustness of conditional BE 
inference. Our analyses confirms that probability of achieving BE could be 
diminished when i) variances of the two drugs are heterogeneous, ii) variances 
are large even homogeneous is maintained and iii) data from the two drugs are 
less correlated in a cross over study. Furthermore, the proposed likelihood 
method allows us to find a range of m where BE is more likely to be achieved. 
When either high heterogeneity or large variances are observed and these 
variances are unknown, the proposed method is particularly effective in making 
inference about the extent that BE is affected by the unspecified variances than 
methods that replace m with sample estimate or integrate out m.  
   The proposed likelihood method is well suited to assess the evidence of BE for 
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log-normal distributed data in both cross-over and parallel designs. Because the 
likelihood function in (5) is presented in two components—a function of F statistic 
and a function of t statistic, both 95% and 90% CLs of  (difference in two mean 
ln(AUC)) generated using TOST can be produced by 95% SCI and 90% SCI 
respectively. They are also comparable to or better than the 95% and 90% HPDs 
obtained by Bayesian posterior distribution of . The proposed likelihood method 
establishes a threshold under which BE is more likely to be achieved and 
measure the strength of evidence using SCIs. We believe the proposed method 
is a better alternative than the usual TOST method. In the cases where BE is 
barely met (i.e., the 90% CI of  barely falls within (-0.223, 0.223)), knowing the 
extent of the variances that could change the outcome from bioequivalence to 
failure or vice versa, as discussed in Sections 3.4 and 3.5, would motivate drug 
developers to address and control the variability, and produce improved 
bioequivalence results.  Ultimately, bioequivalent drug products approved by the 
regulators with stronger evidence will not only benefit patients but also yield more 
satisfactory outcome to drug makers and regulatory agencies.       
   Going forward, in addition to the current work, we will be considering the 
proposed likelihood method for population bioequivalence inference, which is 
more complicated than average bioequivalence. Lastly, sample programs used to 
perform all the calculations including R codes for likelihood and profile likelihood 
methods, Wolfram Mathematica® 7 code for Bayesian model are available for 
request. 
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4.  Inference of equivalence for the ratio of two normal means with 
unspecified variances (Third Topic) 
 
 
 
4.1. Introduction 
 
 
In section 3, we addressed the inference of bioequivalence for log-normal data 
with unspecified variances by expressing the entire likelihood function in the 
product of two components: F-statistic function for variances and t-statistic 
function for the difference of the parameter of interest. For bioequivalence 
studies, U.S. FDA [17] recommends that 90% confidence interval (CI) values for 
the ratio of the relative means for AUC and Cmax of the new and reference drugs 
should fall between 0.80 and 1.25. The distribution of PK parameters is often 
assumed to be log-normal, therefore bioequivalence is usually assessed on the 
difference of logarithmically transformed PK parameters. The proposed method 
in section 3 retains the unspecified variances in the likelihood function via three 
parameters: the ratio of two variances (LQ), the variance of the reference drug $VQ, 
and correlation of the two drugs (W) for cross-over studies only. The word 
“unspecified” means those parameters are included in the model and allowed to 
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vary over a range of values, to show the robustness of bioequivalence inference 
conditional on different values. This method helps identify ranges of variances 
where bioequivalence is more likely to be achieved, which cannot be 
accomplished by methods that replace or remove these parameters such as two 
one-sided tests (TOST), or Bayesian analysis. This method applies to both cross-
over and parallel designs.  
   The endpoint in late phase study for equivalence test is often normal 
distributed. When the untransformed variable is normally distributed, Hauschke, 
et al. [20] gave several examples to justify the need to assess the therapeutic 
equivalence for two treatments using the ratio of two normal means. Liu J-P and 
Weng C-S [31] and Berger and Hsu [5] showed that analyses based on the 
original scale are always more powerful than those based on the transformed 
scale when the distribution is normal. A likelihood-ratio test proposed by 
Sasabuchi has been suggested by several authors including Hauschke et al. 
[20], Berger and Hsu [5] and Hua et al., [22], among others, as appropriate to test 
the null hypothesis of non-equivalence for the ratio of two normal means. Similar 
to the log-normal data, according to the literature, confidence interval inclusion 
such as Fieller confidence set [15] is more commonly used than test procedures 
for normal data.      
   In this topic, we expand the likelihood approach by Diaz-Frances and Sprott 
[14] and what we have covered in section 3 to address equivalence for the ratio 
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of two normal means (H) by expressing the entire likelihood function in the 
product of two components: a function of F-statistic for variances and the a 
function of the t-statistic for H. In essence, the findings regarding inference of 
bioequivalence for log-normal data that is affected by the unspecified variances 
as described in the beginning paragraph and what we have covered in section 3 
can be applied to the inference of equivalence for the ratio of two normal means.  
We show that, the proposed method is effective in investigating the impact of 
variances on the inference of equivalence. Since this has already been 
addressed in section 3, we will only briefly discuss this point for normal data in 
this part. Our focus in this topic is to show additional benefits of the proposed 
method. In general case when model parameters are independent, the proposed 
full-likelihood function method produces results that are same as the likelihood-
ratio test and comparable to Bayesian analysis. In the special case when model 
parameters are dependent, for example the ratio of two variances is directly 
proportional to the ratio of two means, the full-likelihood function yields better 
results in inference about equivalence than the likelihood-ratio test which relies 
solely on the t-statistic function or Bayesian analysis which integrates out the 
variances in the posterior distribution. 
    The remainder of this part of topic is organized as follows. Section 4.2 
describes the proposed likelihood method. Section 4.3 presents the Bayesian 
model. The impact on equivalence by the unspecified variances is described in 
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section 4.4. Comparisons of different methods in general and special cases will 
be shown in section 4.5 followed by summary in section 4.6.   
 
 
4.2. The Likelihood Method 
 
 
In this section, we give details on a whole likelihood function that can be used to 
characterize equivalence for normal data based on bivariate normal distribution. 
The method addresses equivalence trials in cross-over and parallel designs.  
 
4.2.1. Crossover Design  
 
 
Suppose two variables XY and ]Y, C 
 1, … , _, follow bivariate normal (BVN) 
distribution 
                       XY]Y ~cde f`Hgg a , `LQ$Q WL$QWL$Q $Q ah                                       (1) 
In the context of equivalence studies, variables XY and ]Y represent individual 
observations of an efficacy parameter for the two treatments (test and reference) 
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respectively. Parameters in model (1) represent H 
 kXY/k]Y, g 
 k]Y, W 
the correlation coefficient between the two drugs, and LQ the ratio of two 
variances (LQ 
 d°JXY/d°J]Y) and $Q 
 d°J]Y. The correlation coefficient W 
is to address cross-over designs where subjects start with one treatment and 
then are switched to the other treatment usually after a wash-out period, as such 
XY and ]Y are observations from the same subject, while in parallel designs W=0. 
Model (1) assumes there is no sequence or period effect.  
 
Hypothesis and Likelihood-ratio Test 
    It follows from [5, 20, 31] the equivalence hypotheses for the ratio H with the 
pre-specified margins  m, mQ can be stated as, 
: H  m or  Q: H r mQ                                    (2) 
  Ï: m q H q mQ 
These authors further indicated that the size-α likelihood ratio test originally 
proposed by Sasabuchi (1998) [41, 42] is appropriate for the hypotheses in (2) 
and rejects  if  
                     Ð  Ds,t5 and  QÐ q Ds,t5                                      (3) 
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where  ÑÐ 
 uv5xÒwM9z{|}ÓÒ~| , Ô 
 1, 2. Xv 
 ∑ ut , ]M 
 ∑ wt , u 
 ∑ XY  XvQtY , and w 
 ∑ ]Y  ]MQtY .Ds,4 is the (1-?) percentile of the central t-distribution with v 
degrees of freedom.  
Of note,  ÑÐ in (3) is in a general form, the letter C in superscript means crossover 
design. For convenience, we chose the equivalence margins: m=0.8, mQ=1.25 to 
assess equivalence for the ratio of two normal means, however, readers should 
always consider clinically relevant margins in their research and practice.  
 
Fieller Confidence Set  
An equivalence confidence interval (CI) for the ratio of two means can be 
constructed using the generalized Fieller theorem [15]. By solving the quadratic 
equation  ÑÐQ 
 Ds,t5Q  from (3), we obtained the confidence limits as follows: 
        mÆÐ 
 uvwM5RÕÆuvwM5RÕ<5uv<5RÕ<wM<5RÕwM<5RÕ , °Ð 
 9z<t Ds,t5Q  .                    (4) 
After some algebraic, it can be shown that inequalities in (3) are operationally 
equivalent to  
m5Ð  m °_± m=Ð q mQ °_± ]MQ r °Ð                                           (5) 
Equalities in (5) can be interpreted as follows: if the 100(1-2?) per cent Fieller 
confidence set for H has finite length, it is given by the interval ÖÐ 
 m5Ð , m=Ð . 
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Furthermore, Fieller’s confidence set is an interval if and only if ]MQ r °Ð holds 
true. 
    Of the two one-sided tests proposed by Sasabuchi and CI based on the Fieller 
theorem, the former compares  Ð  QÐ with critical t-value under a pre-specified 
value of m mQ; while the latter assumes m is a unknown random variable and 
compare its range of plausible values with the margins m, mQ. 
 
Full Likelihood Function 
   The likelihood approach focuses on showing the statistical evidence instead of 
making decision to choose between equivalence and nonequivalence using the 
hypotheses (2). The likelihood function based on model (1) is in the form of 
 H, g, W, L, $| K, F  9<5</< X  Q9<5< i                   (6) 
where i 
 ∑ u5×< < " ∑ ]Y  gQtY  Q ∑ XY  Hg]Y  gtY 
 {< " w "
tuv5×<< " _]M  gQ  Q ∑ XY  Hg]Y  gtY . 
Without the knowledge of true g and $, a likelihood function of H, L and W can be 
constructed by replacing g in (6) with its restricted maximum likelihood estimator 
(rMLE) ĝH, L, W 
 ×5uv=5×wM×<5Q×=< , followed by replacing $Q with its rMLE 
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$Q 
 Qt5< where B={< " w " tuv5×wM<5<×<5Q×=<  Q uw, and uw 
 ∑ XY tY
Xv]Y  ]M. That is 
RuH, W, L|K, F  5<< {< " w " tuv5×wM<5<×<5Q×=<  Q uw5t               (7) 
Following some algebra, the profile likelihood function in (7) can be factored into 
two parts: 
RuH, W, L|K, F 
 W, L  H|W, L                           (8) 
where           W, L  ` ~5<at                                        (9)             
                   H|W, L 
 1 " <Qt55t                                    (10) 
 
  {¡<=~5<¢¡ {~Q~5< ,  D 
 uv5×wM9z{|}Ø~| 
 uv5×wM¿EØ<}<¢Ø¡£¡<G ` {¡<£ ~}<¢¡  {~a<}}¢< .  
Derivation of (6)-(10) follows similarly to Appendix B. Note that $Q is the sample 
estimate of $Q and differs slightly from $Q . Taking H 
 m and H 
 mQ the 
corresponding D in (10) equal to  Ð and  QÐ respectively. This means H|W, L in 
(10) can produce the results of likelihood ratio test and more importantly the 
likelihood function in (8) which is the product of (9) and (10), will provide more 
information than likelihood ratio test alone on the inference about equivalence. A 
more detailed discussion can be found in Sections 4.4 and 4.5. 
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4.2.2. Parallel Design  
 
 
In a parallel design where samples XY, C 
 1, … , _, and ]¤ , ¥ 
 1, … , ¦ are 
independent (W 
 0), following Diaz-Frances and Sprott [14], 
XY~eHg, LQ$Q, ]¤~eg, $Q. The corresponding expressions of (9) and (10) are:  
                L  ©< §_  1 " ¦  1¨5£©<                                       (11) 
                          H|L  1 " <t=5Q5£©<                                              (12) 
where  
 ~/ª59<«{/§t5<9<¨ 
 t5~<5{ , DQ 
 ` uv5×wM9z{|}Ø~|aQ 
 t·uv5×wM<<=t×<9z<, and $Q 
  {¡<=~=t5Q, 
with d.f. n+m-2.    
Sasabuchi (1998) demonstrated that the size-? likelihood ratio test rejects  if  
                           3  Ds,t=5Q °_±  Q3 q Ds,t=5Q ,                                    (13) 
respectively, where  Y3 
 uv5xwM9z{|}ÓÒ~| , C 
 1, 2. 
Ds,4is the (1-?) percentile of the central t-distribution with v degrees of freedom. 
Algebraic rearrangement shows that condition (13) is equivalent to  
m53  m °_± m=3 q mQ °_± ]MQ r °V 
where 
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mÆ3 
 uvwMÆRÙuv<=R:<wM<5R:RÙ<wM<5RÙ , °% 
 9z<t Ds,t=5QQ  °_± °V 
 9z< Ds,t=5QQ .      (14) 
Condition (14) can be interpreted as follows: if the 100(1-2?) per cent Fieller 
confidence set for H has finite length, it is given by the interval Ö3 
 Em53, m=3G. 
Furthermore, Fieller’s confidence set is an interval if and only if ]MQ r °V holds 
true.  
Compare with method proposed by Sasabuchi and method based on the Fieller 
theorem, the former one plug with m mQ and compare  3  Q3 with critical t-
value; while the later one assume m is a unknown random variable and compare 
its range of plausible values with the margins m, mQ. Both of them involved with 
the Fieller theorem, which is the same as t-statistic function H|W, L in (12). 
Thus inference of H based on (12) should be the same as that based on the 
Fieller confidence set Ö3. In other words the proposed likelihood function, which is 
the product of (11) and (12), is based on more information than methods only 
based on the Fieller theorem.  
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4.3. Bayesian approach 
 
4.3.1. Crossover Design 
 
 
To help derive the Bayesian posterior distribution a change of parameters will be 
needed. Rather than using (1) we employ the following form of distribution for XY 
and ]Y (which bears no deviation from the distribution (1))  
     XY]Y ~cde fgg  , `LQ$Q WL$QWL$Q $Q ah                             (15) 
Under the bivariate normal model (15), as the likelihood function for 
g, g, L, $, °_± W can be expressed as 
               L g, g, L, $, W| K, F  9<5</< X  Q9<5<                 (16) 
where  
 {< " w " tuv5<< " _]M  gQ  Q ∑ XY  g]Y  gtY . 
According to Berger, Bernardo, and Sun [3] and Rubio and Perex-Elizalde  [40], 
the independence Jeffreys prior in (17) is a suitable prior.  
        ²ÚÛg, g, L, $, W  gg5< 9<5<<´ 
 gg5/Q$5QL51  WQ5<´           (17) 
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The posterior distribution of the parameters (g, g, L, $, W) will have the form    
² g, g, L, $, W|K, F   gg5/QL5t5$5Qt5Q1  WQ5<5<´X  Q9<5<     (18) 
Change parameters from g, g, L, $, W to H, g, ·, Ü, W, after some algebra and 
integrating out parameters other than H, the marginal posterior distribution of H 
has the form 
²H|K, F 
¶ ¶ H5<·}< 1  ·}<< 1  WQ }<< 1  ·HQ " ·  2W1  ··H5 ·5·,W2"1−uu1−ρ2βy−x21−·H2"·−2W1−··H−_−12·1−DH,·,W2·±·±W                   
(19) 
Derivation of (19) is similar to Appendix C. 
 
 
4.3.2. Parallel Design 
 
 
In a parallel design where samples XY, C 
 1, … , _, and ]¤ , ¥ 
 1, … , ¦ are 
independent (W 
 0), the likelihood function for g, g, L, °_± $ can be expressed 
as 
      L g, g, L, $| K, F  9£© X  Q9< ¾                               (20) 
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where D
 ∑ u5< < " ∑ E]¤  gGQ¤ 
 {< " w " tuv5<< " ¦]M  gQ. 
According to Berger, Bernardo, and Sun [3] and Rubio and Perex-Elizalde [40], 
the independence Jeffreys prior in (21) is a suitable prior.  
                 ²ÚÛg, g, L, $  gg5< 9< 
 gg5/Q$5QL5                           (21)                                         
The posterior distribution of the parameters (g, g, L, $) will have the form 
             ² g, g, L, $|K, F   gg5/QL5t5$5t55QX  Q9< ¾                 (22) 
Change parameters from g, g, L, $ to H, g, ·, Ü, after algebra and integrating 
out parameters g, · and Ü, the marginal posterior distribution of H has the form 
²H|K, F  ¶ H5<·©}< 1  ·}<< §1  ·HQ " ·¨5< · 1  ·uQ " ·wQ "
1−uuβy−x21−·H2"·−_"¦2·1−DH,··±·                                                              
(23) 
where DH, · is the student’s t-distribution function with (m+n) degrees of 
freedom evaluated at 
DH, · 
 Ý _ " ¦ · §1  ·HQ " ·¨¸1  ·uQ " ·wQ " 1  uuβyM  xMQ1  ·HQ " · Þ ß
1  ·HXv " ·]M1  ·HQ " · à 
Derivation of (23) follows similarly to that of (19). 
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4.4. Inference on equivalence affected by unspecified variances 
 
 
In this section, we illustrate the proposed likelihood method using data from a 
published crossover study, to assess the impact of unspecified variances on the 
inference about equivalence. The unspecified variances are characterized by LQ 
(the ratio of two variances), $Q  (variance for the reference drug) and W 
(correlation coefficient). In this section, we focus on LQ as it is similar to derive 
the impact of $Q  and W, which has been covered in section 3. To do so, we 
construct a likelihood function of H by retaining L in the model while replacing the 
other two with sample estimates in the likelihood function (8). 
 
4.4.1. A normal data set and likelihood ratio test result 
 
 
Data came from the published crossover study by Balthasar  [2]. 
Test drug Cmax:  {140, 13.6, 78.8, 88.0, 54.7, 76.4, 310, 110, 182, 192, 364, 
112}. 
Reference drug Cmax:  {226, 20.1, 51.8, 105, 40.6, 52.6, 175, 135, 337, 326, 
346, 126}. 
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Data came from a simulated cyclosporine bioequivalence study with 12 subjects, 
for a two-treatment, crossover study of 300 mg of cyclosporine administered 
orally. Data were under the assumption of the same parameter values and 
variances for both study periods; consequently, there was no ‘true’ difference 
between the formulations on their rate and extent of absorption. However, these 
parameter values lead to moderately high values of intra-subject variability in 
Cmax (percent coefficient of variation: 23%). Such high variability is not 
appropriate for demonstrating the proposed method. For illustration purpose, we 
take square root of original data, and use the transformed data for analysis. After 
transformation, using the notations in (3), the observed mean values of Cmax are 
Xv=11.25 and ]M=11.81 for test and reference respectively; Sx=202.34, Sy=268.52, 
Sxy=197.22, and correlation is W =0.85. Results of likelihood ratio test are 
summarized in Table 4.1. The 90% Fieller confidence set (FCS) of H=uvwM is (0.8496, 
1.0781) which falls within the equivalence margins (0.8, 1.25), and overall p-
value in rejecting the two one-sided null hypotheses in (2), p=0.0101 is significant 
at 0.05 level. These results clearly suggest sufficient evidence to conclude 
equivalence.  
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Table 4.1. Likelihood ratio test results, Fieller confidence set and equivalence 
assessment for example data 
N 
 
12 
Ratio: uvwM 
 
0.9530 
95% FCS Ratio 
 
(0.8275, 1.1118) 
90% FCS Ratio 
 
(0.8496, 1.0781) 
Likelihood Ratio Test (?=0.05) 
 
p-value (upper) 
 
0.0101 
p-value (lower) 
 
0.0023 
p-value (overall) 
 
0.0101 
Assessment 
 
Equivalent 
 
 
4.4.2. Standardized profile likelihood (SPL) 
 
 
Figure 4.1 shows the plot of the standardized profile likelihood (SPL) for 
RuH, W, L|K, F of H as shown in (8) with L=0.87 and W=0.85 (sample estimates) 
and H in the range of (0.6, 1.4). The standardization was taken to have the 
maximum value of 1 for the vertical scale of the plot: 
  
 
81
SPL=RuH|K, F, W 
 .85, L 
 .87/Ru H 
 uvwM áK, F, W 
 .85, L 
 .87 and 
because both W and L are specified, the component W, L in (8) is cancelled 
out in SPL. According to [38], SPL=1/8 and 1/32 are two common reference lines, 
values that fall into the likelihood interval (LI) corresponding to SPL=1/8 and 1/32 
(namely 1/8 LI and 1/32 LI) indicate “moderate strong” and “strong” evidence 
supported by the data, respectively. Two vertical solid lines represent 
equivalence margins 0.8 and 1.25. The horizontal dashed line, SPL=0.194 was 
obtained by inserting one-sided critical value of t distribution,  t(0.95,11)=1.796 
into SPL. The two points on the SPL curve intersecting with SPL=0.194 are 
0.8496 and 1.0781. Thus using SPL the limits is the same as Fieller confidence 
set. To avoid the confusion with traditional CIs, we name these two limits on the 
SPL curve as SPL CI, and SPL CI with t(0.95,df) as 90% SCI. Hence, with L and 
W taking values given above, the (1-2?)% SCI matches the (1-2?)% CI using 
Fieller confidence set. This can be proven by letting DQ 
 ` uv5×wM9z{|}Ø~|aQ 
 DQ(1-?,Å) in 
(10), which results in H,Q (on SPL) the same as mÆÐ  given in (4) for crossover 
study. 
In Figure 4.1, all 90% SCI, 95% SCI, 1/8 LI and 1/32 LI are comprised within the 
equivalence margins, suggesting strong evidence in favor of equivalence. Note 
that 1/8 LI is very close to 95% SCI (counterpart of 95% CI in SPL setting), which 
is expected as Royall [39] showed for normally distributed random variables 
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that1/8 and 1/32 LIs are approximately the same as the 95% and 99% CIs, 
though 1/32 LI appears to be excessive in the equivalence setting.  
 
Figure 4.1. Plot of SPL of Beta  
 
Note that the width of (1-2?)% SCI equaing to w=m=Ð  m5Ð , is a function containing 
the parameters L and W according to (4). We use contour plots to characterize 
how widths of 90% and 95% SCIs are related to L and W. Figure 4.2 shows the 
contour plots of widths of SCIs using example data, in terms of L and W, with 
sample estimate $. The solid thick line represents the width of 90% SCI=0.2285 
(on left panel) and 95% SCI =0.2843 (on right panel) which are both narrower 
than the width of the Equivalence margins (
 0.45). The data suggests adequate 
evidences of equivalence. Given that there are a range of pairs of L and W 
associated with the same width of a SCI, it should help identify the source of the 
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variability either due to heterogeneity, weak correlation or large variances of the 
two samples that could reduce the probability in achieving Equivalence. 
 
Figure 4.2. Contour plots for the widths of 90% and 95% SCIs 
  
 
4.4.3. Inference about equivalence affected by L 
 
 
In this section, we show the impact unspecified variances have on equivalence 
inference. To do so, we retain L in the likelihood function (8) but replace W with its 
sample estimate W o 0.85. The use of the sample estimate for W allows us to 
explore how inference about equivalence (based on H) can be affected by L. The 
distances between the upper and lower margins are considered in demonstrating 
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the sensitivities of the inferences to L. Sample estimator L = u/w o0.87 is 
chosen as the base value. Alternative values of L can be obtained by certain 
confidence intervals or other meaningful justification. Figure 4.3 presents ratios of 
L at its alternative values against its base value (take reciprocal if ratio is less 
than 1). It also shows the ratios of lengths between the upper and lower margins 
observed at the alternative over the base value of L. The ratios of lengths are 
presented at three levels of SPL, those corresponding to 90% and 95% 
confidence intervals (SCIs) and those at 1/8 LI.   
 
Figure 4.3. Ratios of gamma and length of margin at the alternative values 
against base value 
 
The ratios of margin lengths, and therefore the sensitivities, are dependent of the 
level of SPL. Moreover, the sensitivity relationship between margin length and L 
is understandably complicated. An exact calculation based on (8) gives us a 
range of L where equivalence is achieved using example data is 0.558q
L q1.305 at 90% SCI level. The 90% SCI when L=0.558 is (0.811, 1.200), when 
0.5
1
1.5
2
2.5
3
Gamma SCI95 SCI90 LI 1/8
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L=1.305 is (0.800, 1.093). Even though the 90% SCI is still within the 
equivalence margins, the variances of the two drugs are no longer homogeneous 
raising concerns that one of the drugs carries more variability in rate of 
absorption than the other one.  From this we have shown by methods replacing L 
with its rMLE or sample estimate, it may conceal the extent to which inference 
about equivalence is affected by L. This experience was also noted in [7]. We 
believe that, in the presence of unspecified variances and the extent of 
heterogeneity is a concern, the proposed model RuH, W, L|K, F (8) could help 
determine a range of H where equivalence is more likely to be achieved.    
 
4.4.4. Inference about equivalence affected by $ and W 
 
 
Similarly we refer to two more sensitivity plots to see inference about equivalence 
affected by $ and W. Sample estimate of each parameter is chosen as the base 
value. Alternative values of that parameter can be obtained by certain confidence 
intervals. Figure 4.4 presents ratio of $ at its alternative values against its base 
value (take reciprocal if ratio is less than 1). It also shows the ratios of margin 
lengths observed at the alternative over the base value of $. Three levels of 
margin are considered, as for L. Since the margin length is proportional to $, the 
ratio of $ at alternative values and the corresponding ratios at three levels of SPL 
are constant. The sensitivity relationship between margin length and W is more 
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complicated. Exact calculation by the maximum likelihood function gives range of 
$ and W where BE is more likely to be achieved at 90% SCI level: $ q 7.38 
(0.800, 1.158); W  0.538 (0.800, 1.142). 
 
Figure 4.4. Ratios of sigma and length of margin at the alternative values against 
base value 
 
1
1.2
1.4
1.6
1.8
2
2.2
2.4
2.6
2.8
Sigma SCI95 SCI90 LI 1/8 
  
 
87
Figure 4.5. Ratios of rho and length of margin at the alternative values against 
base value 
 
4.5. Comparison of Different Approaches in Crossover Design 
 
 
In this section, we compare results based on the proposed likelihood method, 
Fieller confidence set and Bayesian approaches using the above data set. Due to 
the partition, when model parameters are dependent, for example the ratio of two 
variances is directly proportional to the ratio of two means, or the correlation 
between two drugs is directly proportional to the ratio of two means,  also can 
be used for equivalence inference based on the ratio of two means. Including F-
statistic function  in this case, like the proposed likelihood method, should be 
able to improve the result than just solely relying on t-statistic function Yâããâ, 
like Fieller confidence set. To make the comparisons more clear, we listed  
1
1.5
2
2.5
3
3.5
4
4.5
5
Rho SCI95 SCI90 LI 1/8
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and Yâããâ for general case and two special cases in Table 4.2, Table 4.3, and 
Table 4.4 respectively. Thus we can see that in general case,  provides no 
information of H, thus the proposed likelihood method performs the same as 
likelihood ratio test or Fieller confidence set. However, in special cases,  
contains information of H. Hence the proposed likelihood method should perform 
better. Results of different approaches are listed in the following tables 4.5, 4.6 
and 4.7, with plots shown in Figure 4.6. 
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Table 4.2. In general case, i.e. L, $ °_± W are independent. 
 Cross-over Design Parallel Design 
 1  WQ
tQLt ¸uLQ " w  2WL uwÞ5t 1Lt ¸uLQ " wÞ5
t=Q
 
 ä1 "
_Xv  H]MQ1  WQ`uLQ " w  2WL uwa HQ  2WLH " LQå
5t
 ä1 " _¦Xv  H]MQ`uLQ " wa _HQ " ¦LQå
5t=Q
 
 
Table 4.3. L 
 æH, where b is a known constant 
 Cross-over Design Parallel Design 
 1  WQ
tQæHt ¸ uæQHQ " w  2WæH uwÞ5t 1æHt ¸ uæQHQ " wÞ5
t=Q
 
 ä1 "
_Xv  H]MQ1  WQ` uæQHQ " w  2WæH uwa HQ  2WæHQ " æQHQå
5t
 ä1 " _¦Xv  H]MQ` uæQHQ " wa _HQ " ¦æQHQå
5t=Q
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Table 4.4. W 
 ÈH, where c is a known constant 
 Cross-over Design Parallel Design 
 1  ÈQHQ
tQLt ¸uLQ " w  2ÈHL uwÞ5t Not applicable 
 ä1 "
_Xv  H]MQ1  ÈQHQ`uLQ " w  2ÈHL uwa HQ  2ÈHQL " LQå
5t
 
Not applicable 
 
Table 4.5. Fieller Confidence Set: 
 General Case Special Case L 
 H Special Case W 
 0.8 I H 
95% FCS of H (0.8275, 1.1118) (0.8277, 1.1048)       (0.7854, 1.1037)        
90% FCS of H (0.8496, 1.0781) (0.8496, 1.0738)        (0.8184, 1.0754)       
 
  
 
91
 
Table 4.6. Proposed Likelihood Method: 
 General Case Special Case L 
 H Special Case W 
 0.8 I H 
95% SPL of H  Ru (0.8275, 1.1118)  
(0. 8275, 1.1118) 
Ru (0.8249, 1.0732)  (0.8277, 1.1048)     
Ru 
(0.8251, 1.1083)         
(0.7854, 1.1037) 
90% SPL of H Ru (0.8496, 1.0781)  
(0.8496, 1.0781)    
Ru 
(0.8451, 1.0476)  
(0.8496, 1.0738) 
Ru (0.8536, 1.0850)  
 (0.8184, 1.0754) 
 
 
Table 4.7. Bayesian Method: 
 General Case Special Case L 
 H Special Case W 
 0.8 I H 
95% HPD of H (0.8001, 1.1184) (0.8244, 1.0633) (0.8421, 1.1268)     
90% HPD of H (0.8301, 1.0779) (0.8444, 1.0393) (0.8683, 1.1033)     
Prob of Hfalls 
within (0.8, 1.25) 0.9707 0. 9905 0.9900 
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Figure 4.6. Plots for general case and two special cases 
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We show that in general case, results of the proposed likelihood method are the 
same as Fieller confidence set, and comparable with Bayesian methods. In 
special case, however, the proposed likelihood method produces narrower 
confidence interval than Fieller confidence set. Hence the proposed likelihood 
method is better than Fieller confidence set or likelihood ratio test for equivalence 
inference. While Bayesian method gives similar length of HPD as the proposed 
method, both 90% and 95% HPDs of H are shifted to the left when L 
 H and 
shifted to the right when W 
 0.8 I H.  
 
 
 
4.6. Summary 
 
 
The results in this paper suggest that the proposed likelihood method that 
measures and presents strength of evidence from the data offers more 
information than just relying on simple hypothesis testing to reach a final 
conclusion on equivalence of two normal means, even though 90% Fieller 
confidence interval and likelihood-ratio test are the most commonly used decision 
making tools. Similar to our findings in section 3, the proposed method can show 
the impact of unspecified variances on the inference of equivalence and also 
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help us identify a range of unspecified variances where the equivalence is more 
likely to be achieved.  
In general case, the proposed likelihood method produces results that are same 
as the likelihood ratio test and comparable to Bayesian analysis. In the special 
case where the ratio of two means determines the ratio of variances, the 
proposed method yields better results (narrower CIs) in inference about 
equivalence than either likelihood-ratio test which relies solely on the t-statistic 
function or Bayesian analysis which integrates out the variances in the posterior 
distribution.  
Our proposed method is comparable to Bayesian method. Length of HPD is 
almost the same as the SPL CI, regardless whether it is a general case or 
special case. However, the HPD is either shifted to left or right, indication the 
Bayesian method may be over estimate resulting from marginalizing out the 
unspecified variances. Our research results show that the proposed likelihood 
method is a better alternative than current analysis method for equivalence 
inference.  
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Appendix A.  Simulation results for scenarios 1, 3 and 4 in Section 2 
Scenario 1:  
Response rates of taking placebo and active control are 0.18, 0.50 for 
HER3+/HER2+; response rates of taking placebo and active control are 0.18, 
0.50 for HER3-/HER2+. 
[Insert Figure A.1 here] 
[Insert Figure A.2 here] 
[Insert Figure A.3 here] 
[Insert Table A.1 here] 
[Insert Table A.2 here] 
In this scenario, HER3/HER2 status is not related to effect size of active control, 
so change of percent of HER3+/HER2+ will not result in constancy assumption 
being violated, and moreover, treatment effect of reference product over putative 
placebo keeps the same. All metrics control type I error rate well enough, except 
a little bit high for metric LRR. Fixed margin method or methods based on it are 
conservative, while synthesis method or methods based on it control type I error 
rate and have higher power. It makes sense under constancy assumption. 
Covariate adjustment methods are stable even when we don’t have any 
covariate effect.  
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Scenario 3:  
Response rates of taking placebo and active control are 0.40, 0.60 within 
HER3+/HER2+; response rates of taking placebo and active control are 0.13, 
0.45 within HER3-/HER2+. 
[Insert Figure A.4 here] 
[Insert Figure A.5 here] 
[Insert Figure A.6 here] 
[Insert Table A.3 here] 
[Insert Table A.4 here] 
In this scenario, HER3/HER2 status is a covariate and moderately interacts with 
treatment arm, so change of percent of HER3+/HER2+ in NI will result in 
constancy assumption being violated. Moreover, increasing the percent of 
HER3+/HER2+ will decrease the “difference” of effect of reference product over 
putative placebo, and also decrease the “difference” of effect of reference 
product over test product. Thus the 10% point corresponding to the biggest 
“Treatment effect of RP over Putative Placebo” in type I error plots. FM and 
methods based on it are under 0.025. Syn is under 0.025 for percent 10%-50%, 
and greater than 0.025 for percent 60%-70%. CovSyn is greater than 0.025, 
while 2sSyn is greater than 0.025 for percent 30%-70%. 
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Scenario 4:  
Response rates of taking placebo and active control are 0.18, 0.78 within 
HER3+/HER2+; response rates of taking placebo and active control are 0.31, 
0.38 within HER3-/HER2+. 
[Insert Figure A.7 here] 
[Insert Figure A.8 here] 
[Insert Figure A.9 here] 
[Insert Table A.5 here] 
[Insert Table A.6 here] 
In this scenario, HER3/HER2 status is a covariate (related with response rate), 
and is highly related with effect size of reference product (interacts with treatment 
arm). Thus change of percent of HER3+/HER2+ in NI would result in constancy 
assumption being violated. Moreover, the higher percent of HER3+/HER2+, the 
bigger difference between treatment effect of placebo and reference produce. 
The first three points, where constancy assumption violated most serious, both 
fixed margin method and synthesis method have inflated type I error rate, with 
synthesis method inflated more. CovFM and 2sFM always control type I error 
rate less than target value 0.025, CovSyn and 2sSyn always have type I error 
rate larger than target value 0.025. Both FM and Syn have type I error rate larger 
than 0.025 at the fourth point, and less than 0.025 at points five and six. 
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Figure A.1. Performance Characteristics Comparisons--Measure of Association: 
Difference. 
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Figure A.2. Performance Characteristics Comparisons--Measure of Association: Log 
Relative Risk. 
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Figure A.3. Performance Characteristics Comparisons--Measure of Association: Log 
Odds Ratio. 
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Figure A.4. Performance Characteristics Comparisons--Measure of Association: 
Difference. 
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Figure A.5. Performance Characteristics Comparisons--Measure of Association: Log 
Relative Risk 
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Figure A.6. Performance Characteristics Comparisons--Measure of Association: Log 
Odds Ratio 
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Figure A.7. Performance Characteristics Comparisons--Measure of Association: 
Difference. 
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Figure A.8. Performance Characteristics Comparisons--Measure of Association: Log 
Relative Risk 
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Figure A.9. Performance Characteristics Comparisons--Measure of Association: Log 
Odds Ratio 
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Table A.1. Scenario 1—Type I Error Rate (Bold rows are percents of HER3+/HER2+ 40%, 50% and 60%)        
Metric Perc_HER3+/HER2
+ 
P T C FM Syn CovFM CovSyn 2sFM 2sSyn 
Difference 
0.1 0.18 0.34 0.5 0.0082 0.0254 0.0056 0.0256 0.0078 0.0253 
0.2 0.18 0.34 0.5 0.0081 0.0241 0.0065 0.0247 0.0076 0.0241 
0.3 0.18 0.34 0.5 0.008 0.0245 0.0077 0.0244 0.0081 0.0244 
0.4 0.18 0.34 0.5 0.0099 0.0256 0.0093 0.0253 0.0098 0.0258 
0.5 0.18 0.34 0.5 0.009 0.0252 0.009 0.0254 0.009 0.0252 
0.6 0.18 0.34 0.5 0.0087 0.0263 0.0089 0.0268 0.0087 0.0261 
0.7 0.18 0.34 0.5 0.0091 0.0254 0.0087 0.0258 0.009 0.0252 
LRR 
0.1 0.18 0.3 0.5 0.0062 0.0291 0.0038 0.0272 0.0061 0.028 
0.2 0.18 0.3 0.5 0.0054 0.0287 0.0055 0.0268 0.0055 0.0285 
0.3 0.18 0.3 0.5 0.0062 0.0257 0.0055 0.0277 0.0062 0.026 
0.4 0.18 0.3 0.5 0.0077 0.0288 0.0076 0.0295 0.0077 0.0291 
0.5 0.18 0.3 0.5 0.0073 0.0304 0.0073 0.0309 0.0073 0.0304 
0.6 0.18 0.3 0.5 0.0051 0.0247 0.0056 0.0245 0.0051 0.0247 
0.7 0.18 0.3 0.5 0.0078 0.0303 0.0078 0.0302 0.0078 0.0311 
LOR 
0.1 0.18 0.319043 0.5 0.0086 0.0258 0.0052 0.0264 0.0081 0.0259 
0.2 0.18 0.319043 0.5 0.0072 0.0259 0.0061 0.026 0.0072 0.0259 
0.3 0.18 0.319043 0.5 0.0077 0.0253 0.0069 0.0257 0.0076 0.025 
0.4 0.18 0.319043 0.5 0.0077 0.0253 0.0078 0.0258 0.0077 0.0255 
0.5 0.18 0.319043 0.5 0.0064 0.0234 0.0066 0.0237 0.0064 0.0235 
0.6 0.18 0.319043 0.5 0.0074 0.0259 0.0073 0.0261 0.0073 0.0256 
0.7 0.18 0.319043 0.5 0.0064 0.0247 0.006 0.0244 0.0063 0.0244 
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Table A.2. Scenario 1—Power. 
Metric P T C FM Syn CovFM CovSyn 2sFM 2sSyn 
Difference 0.18 0.482222 0.5 0.8471 0.9244 0.8479 0.9251 0.8472 0.9246 
LRR 0.18 0.477778 0.5 0.992 0.9985 0.9921 0.9985 0.992 0.9985 
LOR 0.18 0.479894 0.5 0.9333 0.9763 0.934 0.9766 0.9336 0.9764 
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Table A.3. Scenario 3—Type I error rate (Bold rows are percents of HER3+/HER2+ 40%, 50% and 60%)        
 
 
Metric Perc_HER3+/HER2+ P T C FM Syn CovFM CovSyn 2sFM 2sSyn 
Difference 
0.1 0.157 0.311 0.465 0.0012 0.0052 0.0099 0.0313 0.0039 0.0142 
0.2 0.184 0.332 0.48 0.0022 0.0075 0.012 0.0373 0.0082 0.0223 
0.3 0.211 0.353 0.495 0.0029 0.0093 0.0129 0.0423 0.009 0.0298 
0.4 0.238 0.374 0.51 0.0061 0.0179 0.0172 0.046 0.0136 0.0354 
0.5 0.265 0.395 0.525 0.0089 0.0219 0.017 0.0453 0.0142 0.0372 
0.6 0.292 0.416 0.54 0.0124 0.035 0.0178 0.0486 0.0161 0.0437 
0.7 0.319 0.437 0.555 0.0185 0.046 0.0159 0.0432 0.0168 0.0443 
LRR 
0.1 0.157 0.270194 0.465 0 1.00E-04 0.0089 0.043 0.0037 0.0155 
0.2 0.184 0.297187 0.48 2.00E-04 7.00E-04 0.0123 0.0611 0.006 0.0306 
0.3 0.211 0.32318 0.495 3.00E-04 0.0029 0.02 0.0739 0.0121 0.0458 
0.4 0.238 0.348396 0.51 0.002 0.0087 0.0198 0.0761 0.0124 0.0515 
0.5 0.265 0.372995 0.525 0.0055 0.0237 0.0222 0.0757 0.0168 0.0598 
0.6 0.292 0.397089 0.54 0.0171 0.0618 0.022 0.0746 0.0197 0.0697 
0.7 0.319 0.420767 0.555 0.0376 0.1108 0.0169 0.0608 0.025 0.0826 
LOR 
0.1 0.157 0.286903 0.465 3.00E-04 0.001 0.0085 0.0373 0.0035 0.0153 
0.2 0.184 0.313295 0.48 5.00E-04 0.0026 0.0123 0.0521 0.006 0.0264 
0.3 0.211 0.338619 0.495 0.0011 0.0058 0.0167 0.0557 0.0101 0.0355 
0.4 0.238 0.363123 0.51 0.0028 0.0104 0.0162 0.0575 0.0116 0.0414 
0.5 0.265 0.386979 0.525 0.0064 0.0233 0.0196 0.056 0.0156 0.0459 
0.6 0.292 0.410312 0.54 0.0156 0.0421 0.0205 0.0548 0.0185 0.0509 
0.7 0.319 0.433217 0.555 0.0199 0.0584 0.0143 0.0456 0.0162 0.0501 
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Table A.4. Scenario 3—Power. 
Metric P T C FM Syn CovFM CovSyn 2sFM 2sSyn 
Difference 0.265 0.510556 0.525 0.6322 0.7849 0.7401 0.8623 0.7019 0.8369 
LRR 0.265 0.508111 0.525 0.8664 0.9549 0.946 0.9874 0.9198 0.9758 
LOR 0.265 0.509664 0.525 0.6962 0.8374 0.808 0.9118 0.7707 0.8856 
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Table A.5. Scenario 4—Type I error rate (Bold rows are percents of HER3+/HER2+ 40%, 50% and 60%)        
 
 
Metric Perc_HER3+/HER2+ P T C FM Syn CovFM CovSyn 2sFM 2sSyn 
Difference 
0.1 0.297 0.3585 0.42 0.5813 0.744 0.0069 0.0284 0.0275 0.0532 
0.2 0.284 0.372 0.46 0.3157 0.4882 0.0075 0.0274 0.0081 0.0284 
0.3 0.271 0.3855 0.5 0.1267 0.2463 0.0106 0.0345 0.0106 0.0345 
0.4 0.258 0.399 0.54 0.0367 0.0877 0.0129 0.0385 0.0129 0.0385 
0.5 0.245 0.4125 0.58 0.0058 0.0186 0.0125 0.0383 0.0125 0.0383 
0.6 0.232 0.426 0.62 7.00E-04 0.0031 0.0128 0.0403 0.0128 0.0403 
0.7 0.219 0.4395 0.66 0 4.00E-04 0.0138 0.0395 0.0138 0.0395 
LRR 
0.1 0.297 0.353186 0.42 0.4834 0.6683 0.0052 0.0263 0.0233 0.0507 
0.2 0.284 0.361442 0.46 0.2584 0.4391 0.0076 0.029 0.0078 0.0293 
0.3 0.271 0.368103 0.5 0.1133 0.2466 0.0088 0.0386 0.0089 0.0387 
0.4 0.258 0.373256 0.54 0.0307 0.0904 0.0104 0.0416 0.0104 0.0416 
0.5 0.245 0.376962 0.58 0.0059 0.0239 0.011 0.0457 0.011 0.0457 
0.6 0.232 0.379262 0.62 6.00E-04 0.0044 0.0132 0.0473 0.0132 0.0473 
0.7 0.219 0.380184 0.66 0 4.00E-04 0.0102 0.0468 0.0102 0.0468 
LOR 
0.1 0.297 0.35613 0.42 0.5666 0.7386 0.0058 0.0248 0.0282 0.052 
0.2 0.284 0.367601 0.46 0.3134 0.5031 0.0088 0.0304 0.0094 0.0315 
0.3 0.271 0.378769 0.5 0.1313 0.2601 0.0119 0.0379 0.0119 0.038 
0.4 0.258 0.389831 0.54 0.0324 0.0837 0.0121 0.0377 0.0121 0.0377 
0.5 0.245 0.40099 0.58 0.0058 0.0205 0.0128 0.0439 0.0128 0.0439 
0.6 0.232 0.412473 0.62 6.00E-04 0.0027 0.012 0.0465 0.012 0.0465 
0.7 0.219 0.424554 0.66 2.00E-04 5.00E-04 0.0123 0.0446 0.0123 0.0446 
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Table A.6. Scenario 4—Power. 
 
 
Metric P T C FM Syn CovFM CovSyn 2sFM 2sSyn 
Difference 0.245 0.561389 0.58 0.8883 0.9544 0.9268 0.9748 0.9268 0.9748 
LRR 0.245 0.55744 0.58 0.9939 0.9992 0.9968 0.9997 0.9968 0.9997 
LOR 0.245 0.56011 0.58 0.9086 0.9662 0.9451 0.9826 0.9451 0.9826 
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Appendix B.  Partition the entire likelihood function into F-function and t-
function (3)-(7) 
Using the following steps, a maximum likelihood function of , L and W can be 
constructed without the knowledge of true g and $. 
1. Replacing g in (3) by its restricted maximum likelihood estimate (rMLE):  
ĝ, L, W 
 5uv=5wM555Q=<                                      (B1) 
it leads to the maximum likelihood function of , W, L, °_± $, 
Ru, W, L, $|K, F  9<5</< X  Q9<5< c                    (B2) 
where B={< " w " tuv5wM5<5<5Q=<  Q uw, uw 
 ∑ XY  Xv]Y  ]MtY . 
2. Replacing $Q in (A2) by its rMLE, $Q 
 Qt5<, the resulting likelihood 
function is  
  Ru, W, L|K, F  ` ·5<a5t 
 5<< {< " w " tuv5wM5<5<5Q=<  Q uw5t 
   (B3) 
3.  Consider the following F pivotal quantity: 
  
  {¡<=~5<¢¡ {~/Qt5Q5<9<~/t59< 
  {¡<=~5<¢¡ {~Q~5<                       (B4) 
Following some algebra, (A3) can be partitioned into two parts: Ru, W, L|K, F 
 W, L  Yâããâ|W, L                       (B5) 
where   W, L  E5<G< {< " w  Q uw5t 
 ` ~5<at, 
Yâããâ|W, L  ä1 " _Xv  ]M  Q1  WQ`uLQ " w  2WL uwa 1  2WL " LQå
5t

 ç1 " DQ2_  1è5t 
and 
 uv5wM59z{|}~| 
 uv5wM58E}<¢¡£¡<G 9z< , $Q 

 {¡<=~5<¢¡ {~Qt55< .  
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Appendix C.  Derivation of the posterior distribution of Ë in (14) 
The derivation is outlined in the following steps. 
1. Consider the change of parameters (g, g, L, $, W) in (13) to (, g, ·, Ü, W) as 
follows 
 
 g  g, · 
 _$Q_LQ$Q " _$Q , Ü 

_LQ$Q " _$Q 
it leads to 
g 
  " g, L 
 8 ·1  · , $ 
 8 _·Ü  ·Ü5Q 
With some algebra, the posterior distribution of  , g, ·, Ü, W can be shown as 
², g, ·, Ü, W|K, F  ·}< 1  ·}< Üt1  WQ5£´< · X ® 4Q5< ª·, WQ " 1 2W1−··g−é12"é2                                                                         (C1)                                                                        
Where            uQ 
 t ∑ XY  XvQtY , wQ 
 t ∑ ]Y  ]MQtY , uwQ 
 t ∑ XY  Xv]Y tY], 
·, WQ 
 1  ·uQ " ·wQ  2W1  ··uwQ , 
é 
 ª5êuv5=êwM55êêwM55êêuv5«ª5Q5êê« , 
and                                 éQ 
 5ëëìM5δ5í|<=îρ<5ëëìM5δí|5ρ<5ëëìM5δ=í|<5Q5êê . 
Then we have 
², g, ·, Ü, W|K, F  ·}< 1  ·}< ÜÚ51  WQ5£´< · exp ' ÛQ Ü+                      (C2) 
where  Ö 
 _ " 1, and  ï 
 5< ª·, WQ " 1  2W1  ··g  éQ " éQ«. 
115 
 
 
 
2. Integrate (B2) with respect to Ü 0, "∞, and after some algebra we obtain, 
², g, ·, W|K, F ·t5Q 1  ·t5Q 1  WQ t5Q ª1  2W1  ··«5· ·, WQ " éQ5t 
·
ðññ
òñ
ñóç ·, WQ " éQ1  2W1  ··è
5Q ·
ôõõ
õõö1 "
÷ø
øù √_g  é¿ ·, WQ " éQ1  2W1  ··ûü
üý
Q
_þ   



5t=Q

ññ
ññ
Q
 
3. Integrating ², g, ·, W|K, F with respect to g 0, "∞, we obtain 
², ·, W|K, F  ·}< 1  ·}< 1  WQ }< ª1  2W1  ··«5  · ·, WQ "é2−_·1−D,·,W2   
where D, ·, W is the student’s t-distribution function with _ degrees of 
freedom with 
D, ·, W 
  ¿_ · ª1  2W1  ··«§·, WQ " éQ¨ · é 
Finally the marginal posterior distribution of  is  
², |K, F    ¶ ¶ ·}< 1  ·}< 1  WQ }< ª1  2W1  ··«5 · ·, WQ "5é2−_·1−D,·,W2  ±·±W                    
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